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Premise 
My PhD was mainly dedicated to children affected by ALL, either as patients during 
my daily clinical work, either as subjects of my research. 
Here I present the two most relevant works I carried out during this period. 
The first one, that gives the title to this thesis, it’s a project aiming to reveal the 
clinical significance of central nervous system involvement detected by flow 
cytometry. My role in this project comprehended ideation of the research project, 
analysis by flow cytometry of all the samples, recording, collection and analysis of 
clinical and laboratory data and result discussion. 
The second project aimed to define the potential role of autologous hematopoietic 
stem cell transplantation in pediatric relapsed ALL. Autologous hematopoietic stem 
cell transplantation (HSCT) was quite frequently performed for the treatment of 
patient with isolated extramedullary relapse at our institution. We therefore decided 
to collect data of children with extramedullary relapses who underwent HSCT in 
Italy. My role is in this project concerned data collection, result discussion and final 
paper writing (actually submitted). 
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Central nervous system involvement in pediatric acute 
lymphoblastic leukemia detected by 8-color flow 
cytometry: a prospective study 
 
Abstract 
Introduction 
Acute lymphoblastic leukemia (ALL) may involve central nervous system (CNS) in 
3-6% of pediatric patients. Conventional cytology (CC) of cerebrospinal fluid (CSF), 
together with cell count, is the current standard test to define CNS infiltration, 
although sensitivity and specificity are low. Flow cytometry (FC) can identify blasts 
in CSF samples that are negative for cytology with higher sensitivity and specificity. 
Clinical significance of this occult CNS involvement in children with ALL is still not 
clearly understood.  
The aim of this work is to explore the frequency of CNS involvement by FC analysis 
of CSF at diagnosis and at each lumbar puncture during therapy in primary and 
relapsed ALL. Moreover, we want to study prospectively its clinical significance in 
comparison with cytology and cell count. 
Patient and methods 
From 12.09.2013 to 12.09.2016 we included all consecutive patients (aged 1-18 
years) with Philadelphia negative ALL and with ALL isolated bone marrow (iBM) 
relapse diagnosed at our Institution. Parent’s informed consent was acquired and 
the study was approved by the local ethical committee. Treatment schedule and 
definition of CNS involvement were as per AIEOP-BFM ALL 2009 Protocol. 
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Relapsed patients were mainly treated according to AIEOP ALL REC 2003 
protocol.  
At each time point of intrathecal therapy, CSF was collected and analyzed within 
24 hours by cell count, cytology and 8-color FC (precursor-B or T lineage panel). 
A tiny cluster of events with immunophenotype compatible with blasts at diagnosis 
was considered positive by FC (FC+).  
Results 
Eighty-seven patients with primary diagnosis of ALL were included in the study, 
1050 CSF samples were analyzed. At diagnosis, there were 34 (39%) samples 
that were positive by FC, 5 were also CC+. FC+ patients were mainly T-ALL, with 
higher peripheral blast percentage and high-risk features. Relapse incidence and 
mortality were not different between FC+ and FC- groups at diagnosis. 
During ALL treatment, other 37 samples belonging to 19 patients resulted positive 
by FC only. Comparison between FC+ patients during treatment and FC- did not 
result in significantly different outcome. 
Thirteen patients affected by iBM relapsed were included and 109 CSF samples 
analyzed for this cohort. At relapse, 7 patients were positive by FC (53.8%), none 
by CC. Characteristics of FC+ patients and FC- did not differ. Mortality and relapse 
incidence did not show any significan difference between the two groups. During 
relapse treatment, other 20 samples were FC+. In total 6 relapsed patients 
presented ≥2 FC+ samples during therapy, this group presented a higher incidence 
of subsequent relapses compared to FC- patients (83.3% vs 20%, p 0.04).   
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Conclusion 
Our data demonstrated that CNS involvement detected by FC is a frequent finding 
in pediatric ALL at diagnosis and at relapse. The clinical significance is probably 
linked to the persistent CSF positivity rather than to the single sample positivity. 
Actual frontline treatment protocols seem to be able to control CNS submicroscopic 
leukemia.  In relapsed ALL patients, persistent CSF positivity may be a sign of a 
more resistant disease and a negative prognostic factor. A larger group of patients 
and a longer follow up are needed to confirm our observations. 
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Utilizzo della citofluorimetria a 8 colori nella 
determinazione della disseminazione della leucemia 
linfoblastica acuta al sistema nervoso centrale in pazienti 
pediatrici: uno studio prospettico 
 
 
Riassunto  
Introduzione 
La leucemia linfoblastica acuta (ALL) può coinvolgere il sistema nervoso centrale 
(CNS) in circa il 3-6% dei pazienti pediatrici. La citologia convenzionale (CC) su 
liquor cefalorachidiano (CSF), insieme alla conta cellulare, è la metodica standard 
per definire l’infiltrazione al CNS. Sensibilità e specificità di questa tecnica si sono 
però dimostrate scarse. La citofluorimetria (FC) è in grado di identificare blasti in 
campioni che sono negativi all’analisi citologica con maggior sensibilità e 
specificità. Il significato clinico di questo coinvolgimento occulto del CNS nei 
bambini affetti da ALL non è del tutto stato chiarito. 
Con questo lavoro ci prefiggiamo di valutare la frequenza del coinvolgimento CNS 
mediante analisi citofluorimetria del liquor dei pazienti pediatrici con ALL all’esordio 
e alla ricaduta. Inoltre vogliamo studiarne il significato clinico in un lavoro 
prospettico, paragonandolo alle metodiche standard. 
Pazienti e metodi 
Dal 12.09.2013 al 12.09.2016 abbiamo incluso consecutivamente tutti i pazienti di 
età 1-18 anni affetti da ALL (Philadelphia negativa) e ricaduta midollare isolata di 
ALL diagnosticati presso il nostro Centro. È stato acquisito il consenso informato 
10 
 
dei genitori e lo studio è stato approvato dal comitato etico locale. Le modalità di 
trattamento e la definizione di coinvolgimento CNS sono riportate nel protocollo 
BFM-AIEOP ALL 2009. I pazienti con ricaduta sono stati trattati per la maggior 
parte secondo il protocollo AIEOP ALL REC 2003. I campioni di liquor sono stati 
raccolti ad ogni punto previsto per la somministrazione della terapia intratecale e 
sono stata analizzati entro 24 ore tramite conta cellulare, citologia e citofluorimetria 
a 8 colori (con pannelli specifici di linea B o T). In presenza di una popolazione di 
eventi raggruppati in un cluster con caratteristiche antigeniche e fisiche 
sovrapponibili alla popolazione dei blasti dell’esordio, il campione di liquor è stato 
classificato come positivo in citofluorimetria (FC +). 
Risultati 
Ottantasette pazienti affetti da ALL all’esordio sono stati inclusi nello studio, 1050 
campioni di liquor sono stati analizzati. Alla diagnosi 34 (39%) campioni sono 
risultati positivi per FC, 5 di questi lo erano anche per CC. Il gruppo FC+ 
comprendeva soprattutto leucemie a fenotipo T, con più alta percentuale di blasti 
in periferico e caratteristiche di alto rischio. Tra i pazienti FC+ e quelli FC- alla 
diagnosi non è stata dimostrata differenza in termini di ricadute e mortalità. Durante 
il trattamento altri 37 campioni appartenenti a 19 pazienti sono risultati postivi solo 
in FC. La prognosi dei pazienti FC+ e quelli FC- durante il trattamento non è 
risultata significativamente diversa.  
Tredici pazienti affetti da ricaduta midollare isolata di ALL sono stati inclusi. Per 
questa coorte, i campioni di liquor analizzati sono stati in totale 109. Alla recidiva 
7 pazienti sono risultati positivi in citofluorimetria (53.8%), nessuno alla citologia. 
Le caratteristiche dei pazienti del gruppo FC+ e di quello FC- sono risultate 
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sovrapponibili. L’incidenza di ricadute e la mortalità tra i due gruppi non sono 
risultate diverse. Durante il trattamento della recidiva, 6 pazienti in totale hanno 
presentato ≥2 campioni FC+, questo gruppo ha mostrato un’incidenza di ricadute 
successive statisticamente più alta rispetto al gruppo FC- (83.3% vs 20%, p 0.04), 
la mortalità non è risultata diversa.   
Conclusioni 
I nostri dati dimostrano che il coinvolgimento del sistema nervoso centrale 
all’analisi citofluorimetrica è un reperto frequente nelle ALL pediatriche sia alla 
diagnosi che alla recidiva. Il significato clinico di tale dato è probabilmente legato 
alla persistenza della positività del liquor in CF, piuttosto che alla positività del 
singolo campione. Gli attuali protocolli di prima linea appaiono in grado di 
controllare questa infiltrazione sub-microscopica di malattia. Nei pazienti con 
recidiva, la persistente positività del liquor mediante FC potrebbe essere un segno 
di malattia resistente al trattamento ed un fattore prognostico negativo. E’ 
necessario uno studio su una coorte più ampia di pazienti ed un follow-up più 
prolungato per confermare la veridicità di tali osservazioni
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Introduction  
 
Acute lymphoblastic Leukemia (ALL) is the most common malignancy of childhood, 
affecting around 40 children/1.000.000 per year in Europe (1). Improved survival for 
children with ALL is one of the major advance of the contemporary medicine. From a 
survival probability around 30% in the 1960s, in the 1990s the event-free survival 
(EFS) at 5 years for childhood ALL generally ranged from 70 to 83% in developed 
countries (2). Most recent treatment protocols, like those developed at St. Jude 
Children’s Hospital, Memphis (3), reported an EFS at 10 years of 85% (Figure 1). 
Similarly, ALL 2000 trial by BFM study group (Berlin Frankfurt Munster) and Aieop 
(Associazione Italiana di Emato Oncologia Pediatrica) resulted in EFS at 5 years 
of 83% and overall survival (OS) at 5 years of 90% (4). The rational use of multi–
agent systemic chemotherapy over a prolonged duration (2 years) and adequate 
central nervous system (CNS)-directed prophylaxis and therapy as well as 
improved supportive treatment were responsible for the early improvements in 
outcome. Moreover, in the last decades, insights into the biology of ALL and the 
introduction of minimal residual disease (MRD) monitoring have helped to refine 
therapy based on risk of relapse. 
Albeit uncommon, leukemia relapse is still the leading cause of treatment failure, 
affecting approximately 15-20% of patients. A significant percentage of children with 
relapsed ALL still die: survival is 30-50% with intensive chemo and radiotherapy 
approaches and with the use of hematopoietic stem cell transplantation (HSCT) (5,6). 
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Figure 1: Event free survival at 10 years of children affected by Acute Lymphoblastic Leukemia treated with different 
consecutive protocols from 1962 to 2005 at St Jude Children Hospital  Memphis, USA. 
 
Leukemia relapse most frequently involves the bone marrow (BM), but it can occur 
in extramedullary sites, mainly the central nervous system (CNS) and the testis, 
either alone or in combination with BM relapse. Relapses involving the CNS 
account for up to 40% of all relapses, in the face of only 5% CNS involvement at 
diagnosis (7). Moreover, even if total number of relapses is decreased with actual 
frontline treatment, a minor reduction in isolated CNS relapse was observed (8). In 
addition, prevention of CNS dissemination with cranial radiation therapy (CRT) or 
intrathecal (IT) chemotherapy has improved cure rate but, at the same time, has 
been implicated in long term side effects like radiation induced CNS tumors and 
neurocognitive impairment (9-13). Current protocols aim to reduce the use of 
irradiation (14).  Therefore, it is essential to identify patients at higher risk of CNS 
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relapse who may require specific intervention, as well than patients with low risk of 
CNS relapse who my benefit of a less toxic CNS therapy. 
The standard methodology to identify blast in cerebrospinal fluid is based on 
cytology, but this technique has low sensitivity. Flow cytometry (FC) is widely used 
for ALL diagnosis and MRD monitoring, and it has been proven accurate also in 
identifying neoplastic cells in the CSF (15-18).  
With this study, we explored the feasibility of flow cytometric analysis of CSF at 
each lumbar puncture during therapy in primary and relapsed ALL. Moreover, we 
studied prospectively its clinical significance in comparison with cytology and cell 
count. 
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Background 
 
Acute Lymphoblastic Leukemia Diagnosis 
ALL blasts are thought to derive from the clonal expansion of precursor B lymphocytes 
or T lymphocytes. This unrestricted growth is driven by a genetic aberration, such as 
chromosomal abnormality or gene translocation, amplification or mutation. 
In the diagnostic pathway of a child with leukemia, information obtained by morphology, 
immunophenotype, cytogenetics and molecular biology are integrated with clinical data 
in order to define the better treatment for the type of leukemia and the individual patient. 
Morphology 
Acute lymphoblastic leukemia is diagnosed by the presence of lymphoblasts in the bone 
marrow ≥25% of total nucleated cells. Characterization of blasts on morphological 
appearance is part of the routine diagnostic assessment but it has nowadays no 
prognostic or biological meaning. Nevertheless, the definition of complete remission 
(CR) as presence of <5% blasts in bone marrow, it is used for therapy response 
assessment and requires a morphological analysis. The common classification by FAB 
(French American British) defines three subtypes of blasts: L1 cells, the commonest 
type in pediatric ALL, present small and monomorphic cells with elevated 
nucleus/cytoplasm ratio, L2 blasts are more heterogeneous in shape and dimension, 
with irregular nucleus, L3 blasts are the largest, with prominent vacuoli and nucleoli. The 
last subtype it is now considered the leukemic counterpart of Burkitt’s Lymphoma 
(mature B -ALL) (19). 
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Immunophenotype 
Flow cytometry (FC) was developed in the sixties and nowadays it is one of the most 
important diagnostic and research technique, especially in immunology and 
hematology. It is essential for ALL diagnosis and it is a well-established method for 
detecting minimal residual disease. The advantages of FC are: the ease of usage, the 
rapidity of analysis and the low cost as compared to other technique such as molecular 
biology.  
The instrument is formed by a laser light source and a fluidic system. Cells flow into the 
fluidic system and pass through a narrow capillary into a single-cell line where they 
come in contact with the laser beam. Cells cause the light to scatter, two scatter 
parameters are measured by the instrument: forward scatter (FSC) and side 
scatter (SSC). FSC is a measure of cell size, SSC, measured at an angle of 90° to 
the FSC, indicates cellular granularity and nuclear complexity/lobularity. The laser 
light can also excite fluorochromes that, in turns, emit light at a different 
wavelength. Different detectors capture the light emission and convert it in digital 
signal. The power of flow cytometry comes from the ability to integrate the light 
scatter information with fluorescence information. A large number of monoclonal 
antibodies coupled with different fluorochrome are available against surface or 
intracellular antigen (called CD, cluster of differentiation). Cells are stained with 
antibodies and then analyzed by FC, the fluorescence intensity emitted for each 
single fluorochrome is proportional to the antigen expression level on the cell. The 
information obtained are elaborated by a software. Usually, each cell is 
represented by an event and events are displayed as dot plot, contour plot or 
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histograms. Each event is characterized by physical parameters (FSC and SSC) 
and by a fluorescence intensity for each antigen (20). 
Blasts cells typically present aberrant immunophenotype that distinguish them from the 
normal cellular compartment. They may express on their surface antigens that are 
commonly found on normal lymphocytes together with antigens normally expressed by 
other cell lines or at different maturational stage, moreover they can show over-
expression or under-expression of specific antigens (21). This phenotypic signature is 
commonly referred as LAIP (leukemic associated immunophenotype). 
At diagnosis, flow cytometry is essential in lineage assessment. Precursor B (pB) blasts, 
the most common subtypes of pediatric ALL (85%), and T blast are distinguished by the 
expression of lineage specific markers (eg: CD19 for B-ALL, CD7 and CyCD3 for T-
ALL). Combination of different antigens defines the maturational stage of the blasts 
(figure 2) as in the European Group for the Immunological Characterization of 
Leukemias (EGIL) classification (22). 
 
 
Figure 2: Egil classification of ALL (22) 
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Specific blast phenotype may be of prognostic importance. Mature B ALL (leukemic 
counter part of Burkitt’s Lymphoma) is characterized by a high proliferation activity 
caused by the translocations involving MYC gene and it is cured with chemotherapy 
protocol different form pB-ALL (23). Recently, a particularly aggressive subtypes of T 
cell leukemia called ETP (Early T Cell Precursor) ALL has been described by St Jude’s 
Group in collaboration with AIEOP (24).  ETP blasts are defined by a specific phenotype 
that comprises T-lineage markers together with myeloid antigen. Children affected by 
ETP may benefit of a more aggressive chemotherapy approach and frontline use of 
HSCT. 
Moreover, antigen expression on lymphoblast may also correlate, at least in some 
cases, with specific genetic alteration. For example, blasts with t(12;21) typically 
express very low or absent CD45 and CD20, high CD10 and bimodal expression of 
CD34 (25). The translocation t(9;22) (Philadelphia Chromosome)  is frequently found in 
association with myeloid antigen expression, low expression of CD19 and CD38, high 
CD10 and CD34 (26). ALL with translocation involving MLL gene, most frequently 
t(4;11), are characterized by the expression of the marker NG2 (7.1), CD133, CD15 and 
dim expression of CD10 (27,28). 
Flow cytometric analysis, based on the specific immunophenotype defined at diagnosis, 
can be used to detect blasts in bone marrow aspirate during therapy with a sensitivity 
of 1/10-5. This low amount of blasts, that is not detectable by morphological analysis is 
called Minimal residual disease (MRD).  
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Molecular aberration in ALL 
Leukemia development is caused by the disruption of normal cell growth and 
differentiation. Conventional cyogenetich, FISH (fluorescnt in situ hybridization), PCR 
analysis and, recently NGS (next generation sequencing) contribute to the discover of 
an increasing number of genetic lesions in ALL blasts. 
Pediatric B-ALL commonest translocations include t(12;21) [ETV6–RUNX1](25%), 
t(1;19) [TCF3–PBX1](5%), t(9;11) [BCR–ABL1](3%) and translocations involving 
the MLL gene (5%) with various partner fusion genes. High–hyperdiploidy (>50 
chromosomes) accounts for 25% of childhood ALL, whereas hypodiploidy (< 44 
chromosomes) accounts for approximately 1% of cases. Several of these genetic 
changes have prognostic and therapeutic implications and are important in risk 
stratification schemes.  
The overall survival of patients with t(12;21) or high hyperdiploid ALL is generally 
favorable, therefore these patients may benefit of a less aggressive treatment. 
Survival of children with ALL t(9;11)+ has been improved by the addition of tyrosin-
kinase inhibitor to the standard chemotherapy. Hypodiploidy is still a negative 
prognostic factor with current chemotherapy approach. The frequency and 
prognostic impact of MLL rearrangements differ by age. Approximately 80% of 
infants younger than 1 year of age harbor MLL rearrangements and their overall 
outcome is generally poor (5–year survival 50%) despite very intensive therapy 
(29). Around 5% of children presented the translocation t(4;11) which has a 
negative prognostic impact. 
20 
 
With actual techniques, such as genome- wide profiling of RNA and DNA and NGS, 
submicroscopic genetic lesions implicated in leukemogenesis are continually 
discovered. One of these, deletion of IKZF1, predicts a poor prognosis in a group 
of ALL termed Philadelphia like (because of a similar gene expression profile to 
ALL with Philadelphia chromosome) (30). 
T-ALL represent 10-15% of pediatric ALL. Prognosis of T-ALL was historically poor 
but it has improved with current chemotherapy, even if relapsed T-ALL have still a 
dismal outcome. Genetic lesions in T–ALL are diverse and complex and a 
multitude of alterations contribute in the pathogenesis of various subtypes of T–
ALL. Chromosomal translocations are present in approximately 50% of patients 
with T–ALL cases, but unlike B–ALL, their prognostic impact is not well defined 
and they are not used for risk stratification (29). Therefore, for the purpose of this 
thesis, they will be not discussed. 
 
Prognostic factors 
Age (infant or ≥10 years old), presenting leukocyte count (≥50.000/µl), race 
(Hispanic or black), male sex, and T-cell immunophenotype have been considered 
adverse clinical prognostic factors, although their effect is diminished by 
contemporary risk adapted therapy and improved supportive care.  As discussed 
previously, presence of t(4;11), t(9;22), hypodiploidy, IKFZ1 alterations have a 
negative impact on outcome (31). 
Treatment response is predictive of the risk of relapse and is used to assign 
patients to subsequent risk-adapted therapy.  Flow cytometry (detecting aberrant 
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immunophenotypes) and PCR (detecting immunoglobulin or T-cell receptor 
rearrangements) can identify blasts at levels below those detectable by 
microscopic morphologic assessment, allowing the measurement of minimal 
residual disease (MRD). MRD is currently the most powerful prognostic indicator 
in childhood and adult ALL: most treatment protocols stratify patients on MRD 
levels measured during treatment (32, 33). 
 
Leukemia treatment 
Treatment of ALL typically lasts 2–2.5 years, comprising 3 phases: remission-
induction, intensification (or consolidation), and continuation (or maintenance). 
Most of the drugs used were developed before 1970. However, their dosage and 
schedule of administration in combination chemotherapy have been optimized in 
the following decades.  Allogeneic hematopoietic stem-cell transplantation is 
considered for patients at very high risk.  
Remission-induction treatment eradicates the initial leukemic cell burden and 
restores normal hematopoiesis in the majority of children. The chemotherapy 
agents typically include a glucocorticoid (prednisone or dexamethasone), 
vincristine, and asparaginase, with or without anthracycline. 
Intensification (consolidation) therapy is administered after remission-induction to 
eradicate residual leukemic cells. This phase commonly uses high-dose 
methotrexate (MTX) with mercaptopurine or frequent pulses of vincristine and 
glucocorticoids,  asparaginase.  Reinduction therapy comprehends agents similar 
to those used during remission-induction. 
Continuation therapy typically lasts 2 years or longer and comprises mainly daily 
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mercaptopurine and weekly methotrexate with or without pulses of vincristine and 
dexamethasone (2, 4, 31, 34). 
 
Central nervous system leukemia 
Leukemic blasts are able to infiltrate leptomeninges or penetrate in CSF via the 
choroid plexus or into the subarachnoid space via the bridging veins. Moreover, if 
blasts are circulating in PB, they can be introduced either by a CNS hemorrhage 
or iatrogenically at the time of lumbar puncture. The CNS is regarded as a 
therapeutic “sanctuary”, since the blood-brain barrier and blood-cerebrospinal fluid 
barrier prevent adequate cytotoxic level of most chemotherapeutic drugs in the 
CSF. Therefore, blasts can persist in the CNS escaping the effect of either 
chemotherapy and immunosurveillance and finally leading to relapse (35,36).  
Factors associated with a higher risk of CNS relapse in ALL include: T cell 
immunophenotype, hyperleukocytosis, high risk translocations such as t(9;22) and 
t(4;11) and the presence of leukemic cells in CSF (7, 35).  
Patients may present symptoms and signs suggestive of CNS involvement (cranial 
nerve palsy, seizure, altered mental status, headache) or spinal cord compression 
(weakness, paresthesias, bladder dysfunction). However, most patients are 
asymptomatic and CNS leukemia is discovered at the time of lumbar puncture. 
Diagnosis of CNS leukemia (referred as status CNS3 in most protocols) is based 
on: suggestive symptoms and signs (if present) and/or a positive cerebral magnetic 
resonance (MR) or computed tomography (TC), and/or positive CSF analysis. 
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CSF evaluation comprehends usually total white blood (WBC) cell and a red blood 
cell (RBC) count and microscopic morphological analysis after cytospin 
(conventional cytology, CC). CNS3 status requires the presence in CSF of ≥5 
WBC/µl and the identification of blasts by cytological analysis (16, 35). CNS3 
patients, due to the high risk of subsequent CNS relapse, are generally treated with 
additional IT chemotherapy and/or CRT. The clinical significance of low number of 
blasts (<5 /µl) in the CSF (CNS2) is still debatable. Early studies reported a higher 
number of CNS relapses and a poor EFS for this category of patients, as well as 
for those who received a traumatic lumbar puncture (37,38). More recent data do 
not confirm this finding (39, 40). However, it is now known that the classification is 
relevant in the context of the treatment received, as protocols that use early CNS-
directed therapy or prophylactic cranial irradiation did not find differences in CNS 
relapse rates for CNS1 versus CNS2 patients (41). 
 
CNS directed therapy 
CNS directed therapy includes intrathecal administration of chemotherapy and 
cranial irradiation. Cranial radiotherapy (CRT) is very effective in controlling CNS 
leukemia but its efficacy is counterbalanced by several adverse effects (35). 
CRT can pose patients to an augmented risk of tumors (especially CNS 
neoplasms) and a reduction in neurocognitive abilities. Cumulative incidence of 
second neoplasms in patients who received cranial or craniospinal irradiation was 
found to be as high as 20% at 20 years from first diagnosis. Most of these late-
onset tumors were benign or low-grade, therefore late mortality rate was not higher 
in irradiated patients. Nevertheless, with an extended follow up, the risk of 
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secondary neoplasms could even be higher (9). In addition, patients treated with 
CRT have an increased risk of obesity and endocrinopathy (especially growth 
hormone and thyroid hormone deficiency) (13).  
Initial attempts were made to reduce the dose of CRT: 12 Gy were proven 
efficacious to prevent CNS disease in high risk patients, but the reduction in second 
neoplasms did not result significant (42). Most recent trials have omitted CRT from 
first line treatment of ALL: review of treatment outcome showed that CRT was 
associated with a reduced risk of relapse only in the small subgroup of patients 
with overt CNS disease at diagnosis, who had a significantly lower risk of isolated 
CNS relapse and a trend toward lower risk of any CNS relapse. Authors concluded 
that CRT has no impact in relapse rate of pediatric ALL treated with contemporary 
protocols (14).  
Intrathecal (IT) administration of chemotherapy is the standard method used to 
deliver these drugs in the CSF compartment. Metothrexate, cytarabine and 
hydrocortisone are used routinely by IT route in patients with ALL.  The efficacy of 
a single agent (MTX) versus triple IT therapy was explored in a randomized study. 
Authors demonstrated that IT triple therapy reduced the incidence of CNS relapse 
but was associated with an increase in BM and testicular relapse, leading to a poor 
survival rate (43). Therefore, most treatment protocols use IT MTX only. 
Even IT chemotherapy approach is not without adverse events including post-dural 
puncture headache, CNS hemorrhage, leukoencephalopathy, chemical 
meningitides and spinal cord dysfunction (35). Moreover, it is reported that patients 
who underwent CNS prophylaxis with IT therapy only had also some 
neurocognitive deficit in the area of attention and memory (10,11). 
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Based on these premises, it is paramount to have reliable tests that can evaluate 
risk of CNS involvement, in order to minimizing toxicities and increasing cure rate. 
 
Flow cytometry of CSF 
The accuracy and the sensitivity of cytological analysis in defining CNS leukemia 
may be low due to the difficulty in distinguish normal or reactive lymphocytes, 
mostly of T cell lineage, and monocytes. Moreover, cells in the CSF are generally 
scanty and tend to deteriorate quickly (16). For almost 25 years, cell 
immunophenotyping by FC has been routinely used for the detection of lymphoid 
and myeloid malignancies in bone marrow and blood. It is an objective method for 
qualitative and quantitative analysis of cell suspensions and can identify small 
populations of malignant cells with aberrant surface marker expression (20). Since 
2001, when the first report using FC in the identification of CNS leukemia was 
published (44) several reports analyzing both methods have appeared. The work 
of Subira and colleagues collected 168 samples from 30 patients with acute 
leukemia and analyzed them by both FC and CC. They concluded that FC has 
superior sensitivity in comparison to CC, as it is able to detect normal T 
lymphocytes even in sample with low cellularity and can identify blasts when CC is 
negative. The same conclusion derived from the paper by Quijiano et al in which 
123 patients with newly diagnosed aggressive B-cell lymphoma were studied by 
FC and CC (45). 
In the study by Hegde, 51 patients with newly diagnosed aggressive B-cell 
lymphoma were studied: 22% presented CNS involvement by FC but not by CC 
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(46). FC+ group, compared to FC-, had similar characteristics with the exception 
of the involvement of more extra-nodal sites in patients FC+. Other groups (47,48) 
confirmed that FC is able to identify blasts in 10-16% of patients affected by 
aggressive B cell lymphoma. 
Less pediatric studies have been published on this topic: Sayed and colleagues 
described a group of 24 newly diagnosed and 9 relapsed ALL in whom CC, FC and 
molecular biology of CSF were used in order to improve sensitivity in detections of 
CSF involvement (49). Ranta et al studied retrospectively a cohort of 214 pediatric 
ALL patients and found 8% of them positive by FC only at diagnosis, this group 
showed a higher rate of marrow relapse without statistical significance. FC+ 
patients of this cohort were mostly HR and T-ALL (50). 
Established that FC is feasible and can give additional information on CNS 
involvement in leukemia and lymphoma, other groups investigated the prognostic 
impact of this finding in prospective studies. Most studies concerned adult patients 
affected by non-Hodgkin Lymphoma (NHL). In the work by Sancho and 
collaborators 105 patients with aggressive lymphoma were studied at diagnosis: 
14% resulted positive by FC only, these patients showed a higher risk of CNS 
relapse (51). Two other prospective studies (52, 53) came to the same conclusion: 
patients with high risk NHL who had a positive CSF by FC at diagnosis (6-16%) 
showed an increased risk of CNS relapses and a worst OS. Finally, Del Principe 
et al demonstrated in a prospective work that, among 38 adult patients with ALL or 
lymphoblastic lymphoma (LL), those who were FC+ at diagnosis (24%) had inferior 
overall survival (54). 
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Studies regarding children with ALL are less uniform. One hundred and eight 
pediatric patients with ALL were described by Martinez-Laperche and co-authors. 
They performed FC analysis at each time point during treatment, finding that at 
diagnosis FC+ patients were mostly T-ALL with hyperleukocytosis and high risk 
features. CSF positivity by FC during treatment, but not at diagnosis, was 
associated to a higher mortality in this cohort (55).  
A Chinese study randomized FC+ patients to receive or not enhance IT treatment. 
They found that children who received the standard treatment showed a higher 
rate of CNS relapse and higher mortality (56). The authors stated in the discussion 
that in China chemotherapy protocols and CNS prophylaxis are less intensive than 
in Western countries, thus explaining the high rate of CNS relapses. The third study 
that analyzed prospectively pediatric ALL was published last year: among 300 
patients with ALL, 29% had CSF involvement by FC at diagnosis, these patients 
were more frequently T-ALL, younger and with high WBC count on peripheral 
blood. 10% of them were still positive at day 15, subsequent samples were not 
analyzed by FC. In this study 9 relapsed patients were studied by FC, 56% of them 
were positive, but CC results were note reported nor clinical characteristics and 
outcome. The clinical significance of these findings could not be ruled out by this 
study (57).  
FC is able to identify blast even in sample with low cellularity and it is more sensitive 
than CC. Moreover, it helps in discriminating cases that are doubtful by cytology. 
In adults with aggressive non-Hodgkin Lymphoma, it appears to identify patients 
at higher risk of CNS relapse and with adverse prognosis. This may be the same 
for adult ALL/LL although only one study with limited number of patients have been 
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published. Regarding children affected by ALL, the only three papers that studied 
prospectively the prognostic value of FC CSF positivity, all published after the 
initiation of this thesis work, did not reach concordant results. Moreover, almost no 
data are published about the use of CSF FC in pediatric patients with relapsed 
ALL. Therefore, to further address this issue, we conducted the study described in 
the following chapters. 
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Aim of the study 
With this work, we aim to explore the frequency of cerebrospinal involvement by 
FC analysis of CSF at diagnosis and at each lumbar puncture during therapy in 
primary and relapsed ALL. Moreover, we want to study prospectively its clinical 
significance in comparison with cytology and cell count. 
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Methods 
 
Patients 
We included all consecutive pediatric patients (age ≥1 year and <18 years) affected 
by primary ALL and by isolate bone marrow (iBM) relapse of ALL diagnosed at our 
Institution between 12.09.2013 and 12.09.2016. Informed consent was acquired 
from parents or legal guardians and the study was approved by the local ethics 
committee. 
ALL patients were treated according to AIEOP-BFM ALL 2009 Protocol (EudraCT 
Number: 2007-004270-43), patients with presence of t(9;22) are not included in 
this protocol and were therefore excluded from the study. Relapsed patients were 
treated according to AIEOP ALL-REC 2003 protocol, to BFM-IntReALL 2010 
protocol (Eudra-CT Number: 2012-000793-30) or to other treatment strategies. 
CSF samples were collected at each time point of intrathecal therapy 
administration during frontline and relapse treatment. Sample collection and 
analysis were carried out until 31.12.2016, while clinical follow up was updated 
until 20.04.2017. 
 
AIEOP-BFM ALL 2009 protocol definitions 
Definitions of CNS involvement in the AIEOP-BFM ALL 2009 protocol are as follow. 
CNS3 status requires the presence of at least one of the following criteria: 
- Clinical signs or symptoms of CNS involvement (such as cranial nerve 
palsy) 
- Radiological signs detected by cerebral imaging (CT or MR) 
- Presence of blasts in the CSF detected by cytology, with >5 WBC/µl 
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(exception applies for patients classified as CNS2c, see further)  
Patients with no CNS involvement are defined CNS1, they must present CSF 
WBC≤5/µl and absence of blast by cytological analysis of CSF. 
CNS2 status refers to those patients who present blasts by CC, with WBC count 
≤5/µl. A particular CNS2c status is assigned to patients with positive cytology and 
more than 5 WBC/µl, if the following formula is satisfied: CSF WBC count/ CSF 
RBC count < 2 x peripheral blood (PB) WBC count/PB RBC count. 
The following definitions are applied to therapy response assessment by 
morphology: 
• Prednisone good responder (PGR): patients who present in PB blasts 
<1000/µl at day 8  
• Prednisone poor responder (PPR): patients who present in PB blasts 
≥1000/µl at day 8  
• Complete remission (CR): morphological detection of bone marrow 
blasts<5% at the marrow aspirate performed at day 33 or after, no blast in 
CSF by cytology, no evidence of leukemia infiltrate in any other organ by 
clinical examination or by radiological tests 
The following definitions are applied to MRD assessment by flow cytometry at day 
15 bone marrow aspirate: 
• Standard risk (SR) FC-MRD if blasts are <0.1% 
• Medium risk (MR) FC-MRD if blasts are ≥0.1% and <10% 
• High risk (HR) FC-MRD if blasts are ≥10%  
The following definitions are applied to MRD assessment by polymerase chain 
reaction (PCR) at day 33 (time point 1, TP1) and day 78 (time point 2, TP2) bone 
marrow aspirates: 
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• SR PCR-MRD: negative PCR-MRD at both time points 
• MR PCR-MRD: positive MRD at TP1 <10-3 and positive MRD at TP2<10-3 
• Slow early responder (SER) PCR-MRD: positive MRD at TP1 ≥10-3 and 
positive MRD at TP2<10-3 
• HR PCR-MRD: positive MRD at TP2 ≥10-3  
In the AIEOP-BFM ALL 2009 protocol, information regarding biological features 
and therapy response assessment by morphology and MRD are incorporated in 
order to stratify patients into three different risk categories, defined as follow.  
High risk, if at least one of the following situation occurs: 
- Presence of t(4;11) translocation  
- Hypodiploidy (DNA index <0.8 or ≤44 chromosomes by standard karyotype) 
- PPR  
- HR FC-MRD at day 15  
- No RC at day 33 
- HR o SER PCR-MRD 
Medium risk: 
- Absence of high risk criteria and MR PCR-MRD 
Standard risk: 
- Absence of high risk criteria and SR PCR-MRD 
 
 
AIEOP-BFM ALL 2009 protocol treatment   
Chemotherapy administration is divided into 4 treatment phases: Induction, 
Consolidation, Re-Induction, Maintenance (if HSCT is not indicated, see further), 
outlined in Figure 3. 
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Induction 
All patients receive induction treatment consisting in: 
- Phase IA:  prednisone, 4 doses Vincristine (VCR), 4 doses Daunorubicin 
(DNM), 3 IT methotrexate administrations (IT MTX) (or 5 for CNS3 and 
CNS2 patients). Patients with T-ALL and PGR, after day 8, receive 
dexamethasone instead of prednisone. Patients with T-ALL and PPR 
continue with prednisone and receive a dose of Cyclophosphamide (CPM, 
1000 mg/m2).  
- Phase IB: containing oral 6-mercaptopurine (6-MP), 16 doses cytarabine 
(Ara-C) at 75 mg/m2, 2 doses CPM (1000 mg/m2), 2 IT MTX 
Consolidation  
SR or MR patients receive 4 chemotherapy blocks of high dose intravenous MTX 
(HD-MTX 5 gr/m2), each one containing 1 IT MTX. 
HR patients receive 3 high risk blocks as follow: 
- HR-1 block containing oral dexamethasone, 2 doses VCR, 5 doses CPM 
(200 mg/m2), HD-MTX, 2 high doses Ara-C (2 gr/m2), 1 dose Peg-asp, 1 IT 
MTX 
- HR-2 block containing oral dexamethasone, 2 doses vindesine, DNM (30 
mg/m2), HD-MTX, ifosfamide, 1 dose Peg-asp, 1 IT MTX (or 2 if CNS3) 
- HR-3 block containing oral dexamethasone, 5 doses etoposide, 4 high 
doses Ara-C (2 gr/m2), 1 dose Peg-asp, 1 IT MTX 
Re-induction 
- For patient SR or MR, a single Reinduction protocol (Protocol II) is 
administered, containing oral dexamethasone, 4 doses VCR, 4 doses 
Doxorubicin, 1 dose Peg-asp, 1 dose CPM (1000 mg/m2), 8 doses Ara-C 
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(75 mg/m2), oral thioguanine, 2 IT MTX (4 if CNS3) 
- For patient HR, three Reinduction protocols (Protocol III) are administered, 
after the first one and the second one an ad-interim Maintenance phase 
(orally 6-MP and MTX) is provided. Protocol III contains oral 
dexamethasone, 2 doses VCR, 2 doses Doxorubicin, 1 dose Peg-asp, 1 
dose CPM (500 mg/m2), 8 doses Ara-C (75 mg/m2), oral thioguanine, 2 IT 
MTX (3 if CNS3) 
Maintenance 
Patients who are not candidate to HSCT receive oral 6-MP and MTX until 24 
months from the start of therapy. Some particular categories (see further) receive 
IT MTX during this phase. 
 
Randomizations 
In addition, the protocol presents some randomizations: 
- Random 1: patients who present t(12;21) translocation or SR FC-MRD at 
day 15 can be randomized to 2 doses of DNM instead of 4 during Induction 
IA 
- Random HR: patients who present high risk features can be randomized to 
receive adjunctive 4 doses of Peg-Asparaginase (Peg-Asp) during Induction 
IB 
- Random 2: MR patients can be randomized to receive adjunctive 9 doses 
of Peg-Asparaginase during Protocol II and Maintenance 
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Figure 3: Treatment outline according to AIEOP-BFM ALL 2009 protocol. 
 
CNS directed therapy in the AIEOP-BFM ALL 2009 protocol 
CNS directed therapy/prophylaxis comprehends intrathecal administration of 
methotrexate and cranial radiotherapy (CRT). Methotrexate is administered 
intrathecally at a dose depending on patient age: 8 mg to children ≥1 year and <2 
years old, 10 mg to children ≥2 years and <3 years old, 12 mg to children ≥3 years 
old. CRT is administered at 12 Gy or 18 Gy. 
The following patient categories are defined in the protocol, each one receives 
different CNS directed therapy: 
1. CNS1, pB-ALL patients, with MR or SR features, receive 11 IT 
administrations of Methotrexate (standard IT therapy), none during 
Maintenance 
2. CNS1, pB-ALL patients, with HR features, receive 14 IT administrations of 
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Methotrexate during treatment and additional 6 during Maintenance (if they 
are not candidate to HSCT) 
3. CNS1, T-ALL patients, <2 years of age or with PB WBC<100.000/µl at 
diagnosis and no HR features, receive standard IT therapy and additional 6 
IT MTX during Maintenance 
4. CNS1, T-ALL patients, ≥2 years of age, with PB WBC >100.000/µl at 
diagnosis or HR features, receive standard IT therapy and CRT (12 Gy) 
during interim Maintenance (if they are not candidate to HSCT) 
5. CNS2 patients receive 2 additional IT MTX during Induction IA, subsequent 
CNS treatment is administered on the same criteria of CNS1 patients 
6. CNS3 patients receive additional 4 IT MTX during therapy if SR or MR, or 6 
if HR; moreover, they receive CRT at 12 Gy if <2 years of age, 18 Gy if ≥2 
years of age 
7. Patients with HR features, for whom allogeneic HSCT is indicated, do not 
receive CRT. They are treated with TBI as part of the conditioning regimen, 
plus a cranial boost if CNS3. 
 
Hematopoietic stem cell transplantation criteria in AIEOP-BFM ALL 2009 
Allogeneic HSCT should be offered to patients presenting at least one of the 
following HR criteria: 
- no CR at day 33  
- HR PCR-MRD 
- t(4;11) translocation + MR, SER or HR PCR-MRD 
- hypodiploidy + MR, SER or HR PCR-MRD 
- T-ALL, PPR + HR PCR-MRD or no MRD results 
37 
 
 
Relapse definition 
ALL relapse is defined as the recurrence of leukemia after CR achievement. It may 
involve bone marrow, CNS or extramedullary sites. The following definitions were 
applied in our study: 
• Isolated BM (iBM) relapse: ≥25% of blasts by morphological examination of 
bone marrow smear, with no CSF blasts by cytology, no evidence of 
leukemia infiltrates in any other organ  
• Isolated CNS (iCNS) relapse: CSF with blasts detected by cytology and >5 
WBC/µl or clinical signs or symptoms of CNS involvement (such as cranial 
nerve palsy) or radiological signs detected by cerebral imaging  
• Combined Relapse: ≥5% BM blasts together with another leukemia 
localization 
Depending on time between the onset of relapse and primary diagnosis, the 
following terms are used: 
- very early relapse, if it occurs less than 18 months from primary diagnosis,  
- early relapse if it occurs later than 18 months from diagnosis and less than 
6 months from treatment discontinuation 
- late relapse if it occurs more than 6 months from treatment discontinuation 
 
In the AIEOP ALL 2003 protocols, patients were stratified according to 3 prognostic 
factors (site of relapse, time to relapse and phenotype) into 4 risk categories: 
- S1 late extra-medullary relapses 
- S2 early or very early extra-medullary relapses, early pB-ALL combined 
relapses, late pB-ALL iBM relapses 
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- S3 early pB-ALL iBM relapses 
- S4 T-ALL iBM relapses, very early pB-ALL iBM or combined relapses 
 
Treatment of relapse 
Therapy outline according to Aieop ALL REC 2003 protocol is reported in figure 4.  
Patients with iBM relapse were treated according to S2 or S3-S4 arm. Therapy for 
S2 patients comprehends randomization between induction with two blocks (F1 
and F2, arm A) or a continuous therapy (protocol IA-IDA, Arm B).  
• Block F1 
Prednisone for three days, followed by dexamethasone, 2 doses VCR, ev 
MTX (1 gr/m2), 1 dose L-Asparaginase, 2 IT MTX 
• Block F2 
Dexamethasone, 2 doses VCR, 4 doses of HD ARA-C (3 gr/m2), 1 dose L-
Asparaginase, 1 IT MTX 
 
 
Figure 4: outline of AIEOP ALL REC 2003 protocol treatment 
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• Protocol II- IDA 
Dexametasone, 4 doses L-Asparaginase, 4 doses VCR, 4 doses idarubicin, 
1 dose CPM (1000 mg/m2), 8 doses Ara-C (75 mg/m2), oral 6-MP, 4 IT MTX 
• Protocol IA-IDA 
Prednisone, 4 doses VCR, 4 doses idarubicin, 8 doses L-Asparaginase, 3 
IT MTX 
• Block R1 
Dexamethasone, oral 6-MP, 2 doses VCR, ev MTX (1 gr/m2), 2 doses of HD 
ARA-C (2 gr/m2), 1 dose L-Asparaginase, 1 IT MTX 
• Block R2 
Dexamethasone, oral thioguanine, 1 dose vindesine, ev MTX (1 gr/m2), 5 
doses of ifofamide, 1 dose L-Asparaginase, 1 dose daunomicine, 1 IT MTX 
Patients stratified as S3-S4 were randomly assigned to arm A (IDA-AraC followed 
by FLAG) or Arm B (FLAG-Myocet followed by FLAG) 
• IDA-Ara C 
Oral prednisone, 1 dose idarubicine, 5 doses HD ARA-C (3 gr/m2), 2 IT MTX 
• FLAG (+/- Myocet) 
Fludarabine, 5 doses HD ARA-C (3 gr/m2), 1 dose Myocet (liposomal 
doxorubicine), 2 IT MTX G-CSF (granulocyte- colony forming unit) 
For S3-S4 patients, HSCT is indicated from matched familiar donor (MFD), 
matched unrelated donor (MUD) or mismatched donor (MMD). For patients with 
S2 relapse, HSCT is indicated in case of MFD availability or from MUD if relapse 
occurred within 48 months from diagnosis. Fore relapses occurring >48 moths 
from primary diagnosis, the decision to proceed to MUD or MMD is based on 
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MRD levels. 
 
CSF Samples 
At each point of intrathecal therapy, patients underwent lumbar puncture under 
deep sedation. Before MTX administration, CSF was collected by clinicians in two 
vials, containing approximately 1 ml of CSF each.  The first vial was send to the 
central laboratory of our hospital (Laboratorio Centrale, Azienda Ospedaliera di 
Padova), the second one to our laboratory in the Pediatric Onco-hematology Unit. 
All samples were analyzed within 24 hours by cell count, cytology and 8-color flow 
cytometry. Operators were blinded to the results of the 2 other techniques. 
Clinicians were blinded to FC results. 
Cell count was performed in the central laboratory by the automatic cell counter 
XE5000 (Sysmex Europe, Gmbh, Germany) that is specifically dedicated to CSF 
samples. Results were expressed as number of WBC and RBC/µl.  
In our laboratory, each CSF sample was divided in two aliquots: one was used for 
cytology, one for flow cytometry. Slides were prepared after cytospin centrifugation 
by Shandon Cytospin 4 centrifuge (Thermo Electron Corporation). First, the filter 
cards were wet with Hanks’ Salt solution (Biochrom Gmbh). Each sample was 
loaded into the cytospin centrifuge and a filter card and a glass slide were added 
in the position provided.  Samples were centrifuged at 450 rpm for 10 minutes. 
After cytocentrifugation, slides were dried and stained with May-Grunwald Giemsa 
stain by an automated instrument ADVIA S60 (Bayer). Cytological analysis with 
Leitz Wezlar optic microscope was performed by an expert morphologist. 
For flow cytometry, each CSF sample was centrifuged at 1200 rpmi for 5 minutes. 
The sample was resuspended in 100µl of PBS (+1% bovine albumin) and 
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incubated with a mixture of fluorescence-conjugated antibodies for 10 minutes in 
the dark. An antibody combination was used for B-lineage ALL, and another one 
for T-ALL (Figure 5). Antibodies were purchased from Beckton Dickinson 
Biosciences (BD) and Beckman Coulter.  
 
A  
FITC PE PC5 PC7 APC APC Cy7 Horizon V450 Horizon V500 
CD58 CD10 CD34 CD19 CD3 CD20 CD38 CD45 
 
B 
FITC PE PC5 PC7 APC APC Cy7 Horizon V450 Horizon V500 
CD99 CD5 CD34 CD38 CD33 CD3 CD7 CD3 
 
Figure 5: B-lineage ALL (A) or T-lineage ALL (B) antibody combination and the 
corresponding conjugated fluorochrome used for FC CSF analysis   
 
After incubation, 3 ml of PBS+1% BSA were added and the sample was then 
centrifuged at 1200 rpmi for 10 minutes. The supernatant was discarded and the 
pellet resuspended in 300µl of PBS+1% BSA. Sample were run until exhaustion 
on FACSCanto II flow cytometer (Becton Dickinson Biosciences, BD, San José, 
CA, USA) and analyzed with FACS Diva software (BD). 
For analysis, dead cells and debris were excluded in FSC/SSC dot plots (primary 
gate). For pB-ALL a second gate was set on CD19 positive events, blasts were 
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identified on CD45/CD10/CD58/CD34/CD20/CD38 expression, normal T cells 
were identified based on CD3/CD45 expression, monocytes on CD58/CD45 
expression, normal B cells on CD45/CD19/CD34/CD20. For T-ALL a second gate 
was set on CD7 positive events, blasts were identified on 
CD45/CD3/CD5/CD99/CD38 expression, normal T cells were identified based on 
CD3/CD5/CD7/CD45 expression, monocytes on CD33/CD45 expression (58). 
A tiny cluster of events with immunophenotype compatible with blasts at diagnosis 
was considered positive by FC (FC+). If a cluster of events with aberrant 
phenotype, but very different from blasts at diagnosis was found, the sample was 
defined as uncertain (FC+/-). Total number of events, number of events identified 
as blasts, normal T-lymphocytes, monocytes, normal B-lymphocytes were 
reported. Sample volume was also recorded. 
 
Statistical analysis 
Categorical variables were compared using Chi-square test (Pearson) performed 
using in-silico.net. Continuous variables were compared using Mann-Whitney-
Wilcoxon test for unpaired data performed using www.astatsa.com. Two-sided p 
values <0.05 were regarded as significant.  
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Results 
 
CSF from patients with de-novo ALL 
 
Characteristics of patients 
A total of 87 patients with de-novo ALL were recruited in this study. 
Patient characteristics were the following: 54 (62.0%) male, 33 (38.0%) female, 
median age at diagnosis was 4.7 years (range 1.4-17.7 years). Leukemia 
immunophenotype was precursor B (pB) in 86.2% of cases, T in 13.8%. The 
translocation t(12;21) was found in 19 (21.8%) cases, t(1;19) in 2 (2.3%) cases, 
the rest were negative for each of the following: t(12;21), t(9;22), t(4;11), t(1;19).  
At the time of lumbar puncture, 14.9% of patients had hyperleukocytosis (white 
blood cells in peripheral blood >50.000/µl) and median blast percentage in PB was 
38% (0-93%). Six children (6.9%) showed blasts at CSF cytological analysis, 80 
were negative and 1 was diagnosed as CNS3 in another center. Flow cytometric 
analysis of CSF resulted positive in a total of 34 (39.1%) children at diagnosis. 
Five patients (5.8%) were classified as CNS3 at diagnosis: 3 cases for CC 
positivity, 1 case for cranial nerve palsy (CC was negative) and 1 case was 
diagnosed as CNS3 in another center (CSF was not available for analysis at 
diagnosis). Seven patients (8.3%) were classified as CNS2: of those 3 presented 
positive CC and low cell count (<5/µl) as per protocol CNS2 definition, 4 patients 
were negative by laboratory analysis but treated as CNS2 for clinicians’ decision. 
A total of 75 children resulted CNS1.  Patients characteristics, grouped by CNS 
status, are shown in Table 1.   
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Risk stratification as per protocol resulted in 25 (28.7%) HR, 44 (50.6%) MR and 
18 (20.7%) SR.  
Median follow up was 24.8 months (range 7.2-43.9 months). Two patients 
experienced an isolated bone marrow (iBM) relapse, no CNS or combined relapses 
occurred. Among relapsed patients: one was a pB-ALL, CNS1, FC+ at diagnosis, 
who was classified HR for molecular MRD; he presented a very early iBM relapse 
and subsequently died of disease progression. The other one was T-ALL, CNS1, 
FC+ at diagnosis and at following time points, HR for not CR at the end of induction; 
he presented a very early iBM relapse and subsequently died of a septic shock 
during a neutropenic phase. Other two patients died for treatment related 
complications: 1 patient (pB-ALL, CNS1, FC-, HR for molecular MRD) died of a 
complicated pneumonia, the other one (T-ALL, CNS3, FC+ at various time points, 
HR for not CR at the end of induction) underwent HSCT from a matched unrelated 
donor and died soon after transplantation of multiorgan failure. 
Statistical analysis revealed that CNS3 status was associated, in our cohort, with 
T immunophenotype, positive CSF cytology and high risk features (Table 2). CNS2 
patients showed higher frequency of positive CSF cytology, CNS1 patients were 
mainly pB-ALL with negative CSF cytology. Gender, age, presence of t(12;21), 
hyperleukocytosis, peripheral blast percentage and FC at diagnosis did not differ 
among CNS3, CNS2 and CNS1 patients. Number of relapses and deaths, as well, 
were not differently distributed.  
A total of 1072 CSF samples were collected and analyzed by cell count and 
cytology, FC was not performed in 22 samples for inadequate material. 1050 
samples were included in the analysis: 84 were collected at diagnosis, 966 at other 
time points. Median volume was 400 µl (range 50-1500 µl). 
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Peripheral blood contamination was determined by the presence of RBC by cell 
count and/or cytology: a total of 323 out of 1050 samples (30.7%) were positive for 
RBC.  
Using flow cytometry, we observed that the large majority (90.1%) of samples 
contained T lymphocytes, a small proportion showed also monocytes (17.5%) or 
mature B lymphocytes (1.7%). After exclusion of samples with RBC contamination, 
these normal cell populations were still evident ( 89.7% of samples contained T 
lymphocytes, 17.5% monocytes and 0.9% mature B lymphocytes). 
 
CSF evaluation by flow cytometry at diagnosis 
Eighty-four CSF samples had available FC analysis at diagnosis (Table 3).  
Flow cytometry showed blasts in 34 samples (39.0%) at diagnosis: 5 were positive 
by CC (3 CNS3 and 2 CNS2), 29 negative (28 CNS1, 1 patient defined CNS2 for 
clinical reason but with negative CC). Fifty (57.5%) patients resulted FC negative, 
they were all negative by CC with one exception. The latter showed blasts at CC 
analysis, low cell count (<5/µl) and was thus classified CNS2, but FC revealed only 
mature T and B lymphocytes. 
FC+ samples were most frequently CC+ as compared to FC- samples (14.7% vs 
2%, p 0.03). RBC contamination and median CSF WBC count were significantly 
higher in specimens that were FC+ in comparison with FC- (44.2% vs 6.0%, 
p<0.0001 and 1/µl vs 0/µl, p 0.04, respectively). Median volume between FC+ and 
FC- samples did not differ (450 µl vs 400 µl). 
Among FC+, median number of events regarded as blasts by FC was 54 (range 4-
3284). In most of CSF samples, blast immunophenotype was similar to the one of 
blasts detected in bone marrow. In 9/24 (37.5%) children affected by pB-ALL, CSF 
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blasts showed CD34 downregulation in comparison to marrow blasts (data not 
shown). 
Clinical characteristics of patients who showed FC+ CSF at diagnosis in 
comparison with FC- are listed in Table 4. FC+ patients (total number 34) had more 
frequently T-ALL immunophenotype (23.5% vs 6.0%, p 0.02), and a higher 
percentage of peripheral blast (median 63% vs 25%, p 0.0003). Moreover, FC+ 
patients, compared to FC-, were mostly stratified as HR (41.2% vs 20%, p 0.03) 
and SR (32.3% vs 14%, p 0.04). The two groups did not differ for male/female ratio, 
median age, presence of t(12;21), WBC count in peripheral blood (>50.000/µl or 
<50.000/µl) and CNS status. Among FC+ patients, there were 3 CNS3 (for positive 
CC), 3 CNS2 (2 for CC+, 1 CC- but classified CNS2 for clinical reasons) and 28 
CNS1. Among FC- patients, 1 patient was CNS3 for cranial nerve palsy (CC was 
negative) and 4 patients were treated as CNS2 by clinicians but were negative by 
cytology. Relapses and deaths of any cause were more frequent in the FC+ group 
of patients (5.8% vs 0% and 8.8% vs 2%, respectively) but the difference did not 
result statistically significant. The number of deaths due to disease progression or 
to treatment were not different between the two groups. 
Twenty-eight patients (32.2%) were classified as CNS1 but showed occult CNS 
involvement by flow cytometry at diagnosis (CNS1 FC+), while 45 (60.0%) were 
totally negative for CNS involvement (CNS1 FC-). Characteristics of samples and 
patients of the two groups (CNS1 FC+ vs CNS1 FC-) are listed in table 5 and 6. 
The proportion of samples containing RBC was higher in the group FC+ compared 
to FC- (32.1% vs 4.4%, p 0.001). Median volume and median WBC count/µl did 
not differ between the two groups. Median number of events identified as blast by 
FC were 50 (range 4-2687).  
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CNS1 FC+ patients had more frequently T-ALL phenotype (17.9% vs 2.2%, p 0.04) 
and a higher peripheral blast percentage (median 60% vs 27%, p 0.001). 
Moreover, frequency of SR patients was higher in FC+ group as compared to FC- 
(32.3% vs 11.1%, p 0.02) and MR patients were more frequent in the FC- group 
(68.9% vs 28.6%, p 0.0008). The two groups did not differ in gender, median age, 
presence of t(12;21), peripheral blood WBC count (>50.000/µl or <50.000/µl) and 
HR features. Two patients, both CNS1 FC+ at diagnosis, experienced an iBM 
relapse and subsequently died. However, relapse incidence and mortality did not 
result significantly different between CNS1 FC+ and CNS1 FC- patients. 
 
CSF evaluation by flow cytometry during treatment  
During treatment, a total of 966 CSF samples from 87 ALL patients were analyzed 
by flow cytometry. CSF data are presented in Table 7. 
No sample resulted positive by cytology, while 37 (3.8%) were positive by flow 
cytometry, and 11 (1.1%) were defined as “uncertain” by flow cytometry (FC +/-). 
The frequency of samples contaminated by RBC was similar in each group (FC+ 
32.4%, FC+/- 27.3% and FC- 31.3%), as was the median CSF volume. FC+ 
samples had higher median number of CSF WBC/µl than FC- (1/µl vs 0/µl, p 0.03). 
Median number of WBC/µl and median number of events did not differ between 
FC+ and FC+/-. 
CSF specimens that were positive by flow cytometry were distributed during 
treatment as follow: 6 at day 15, 3 at day 33, other 2 during Induction IA (both 
adjunctive lumbar punctures for CNS3 patients), 8 during Induction IB, 12 during 
Consolidation phase and 6 in Reinduction. No FC+ sample was found during 
Maintenance. Uncertain sample by FC were distributed as follow: 2 in Induction, 4 
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in Consolidation, 3 in Reinduction, 1 at the end of therapy, 1 in other treatment 
phases. 
CSF specimens that resulted FC+ during treatment referred to 19 patients. 
Characteristics of children with FC+, FC+/- or FC- samples during treatment are 
listed in Table 8. Compared to patients with FC- samples, those with FC+ samples 
were mostly affected by T-ALL (47.4% vs 3.2%, p <0.0001), CNS3 status at 
diagnosis (26.3% vs 0%, p<0.0001) and HR leukemia (57.9% vs 20.6%, p 0.002). 
Moreover, FC+ patients during treatment were more frequently FC+ at diagnosis 
(57.8% vs 33.3%, p 0.02). Gender, median age and presence of t(12;21) 
translocation did not differ between patients FC+ and FC- during treatment. 
Characteristics of patients who presented at least one FC+/- sample during 
treatment did not differ to those of FC- patients (not shown). 
Relapses were almost uniformly distributed: 1 (5.3%) occurred in the group of 
patients with FC+ during treatment, the other one (1.5%) in the group of patients 
FC- (this boy was FC+ only at diagnosis). Number of deaths did not differ, 2 were 
in the FC+ group (10.5%) and 2 in the FC- (3.0%). No relapses nor deaths occurred 
among FC+/- patients.  
We subsequently grouped patients on the basis of the number of samples FC+ or 
FC+/- from diagnosis during the entire treatment course. One group included 
patients with 2 or more FC+ (or FC+/-) samples (15 pt, 17.2%), one group patients 
with only one FC+ (or FC+/-) sample (28 pt, 32.2%) and one group patients who 
were always negative by FC (44 pt, 50.6%). Characteristics of patients of those 
three groups are listed in Table 9, statistical analysis in Table 10. Patients with 
more than 2 samples positive by FC, compared to those with only 1 FC+ or those 
FC-, had mostly T phenotype (60% vs 7.1% and 2.3%, respectively, p 0.0002 for 
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both), absence of t(12;21) translocation (0% vs 28.6%  and 25.0%, respectively), 
CNS3 status (26.7% vs 3.6% and 0%, respectively), HR features (80.0% vs 14.3%  
and 20.5%, respectively, p<0.0001 for both) and a low number of MR patients 
(6.7% vs 50% and 65.9%, respectively). Moreover, as expected, in comparison 
with FC- group, patients with more than two FC+ samples showed higher rate of 
FC+ at diagnosis (86% vs 0%, p<0.0001) and lower rate of CNS1 patients (60% 
vs 95.5%, p 0.0005). Gender and median age did not differ. Patients with only 1 
FC+ sample had clinical characteristics comparable to FC- patients with the 
exception of a higher frequency of FC+ at diagnosis (75% vs 0%, p< 0.0001) and 
of SR patients (35.7% vs 13.6%, p 0.03).  
There were 1 relapse in the group with more than 2 FC+ samples (6.7%), one in 
the group with 1 FC+ (3.6%) and no relapses in the FC- group; however, the 
difference was not statistically significant. Number of deaths did not differ 
significantly among the three groups. 
Children with more than 2 CSF samples positive by flow cytometry showed 
positivity along all the treatment phases (Table 11), 26 FC+ samples were evident 
during Induction, other 26 in other treatment phases.  
 
Relapsed ALL 
 
Characteristics of patients 
Thirteen patients with isolated BM relapse met the inclusion criteria.  
Characteristics of patients are described in Table 12: 8 males, 5 females, 12 pB-
ALL, 1 T-ALL. Median age at relapse was 9.5 years (range 2.7- 12.37). Regarding 
molecular characterization, 1 patient presented t(9,22), 1 t(12;21) and one T-ALL 
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patient had FLT3-ITD mutation. Six were late relapses, 1 early relapse, 4 very early 
relapses and 2 occurred after HSCT. Patients were mostly treated according to 
AIEOP ALL- REC2003 protocol (61.5%), 30.8% received other therapy, only one 
patient was treated with the recent IntReALL-SR protocol. HSCT was performed 
from a matched family donor in 3 patients, from a matched unrelated donor in 4, 
from a partially matched (haploidentical) family donor in 4. Two patients died of 
disease progression before undergoing HSCT.  
Median follow up was 18 months (range 4.8-82.3 months). During this period 7 
patients presented a subsequent relapse: 5 isolated BM relapses, 2 isolated CNS 
relapses. In total 7 patients died at a median follow up of 11.5 months from first 
relapse (range 4.8-82.3 months). Six out of 7 patients with a second relapse died: 
2 of toxicity, 4 of disease progression. One patient died of transplant related 
mortality (TRM) in second complete remission. The only patient who is alive after 
the second relapse (iCNS), is affected by pB-ALL with t(9;22)+: she had a third iBM 
relapse, after this she remained in CR for a long period with tyrosine kinase inhibitor 
therapy, unfortunately she recently developed a fourth (iCNS) relapse. 
CSF samples included in the analysis were 109, 13 samples at relapse onset, 96 
during relapse treatment. 
RBC contamination was evident either by cytology or by cell count in 31 samples 
(27.9%). By flow cytometry we observed that most samples contained T 
lymphocytes (82.8%), few samples showed also monocytes (16.2%), no mature B 
lymphocytes were detectable. Normal blood cell populations were evident also in 
samples not contaminated by RBC: 80.0% of samples contained T lymphocytes, 
15.0% contained monocytes. 
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CSF evaluation by flow cytometry at relapse 
At relapse, 7 samples were positive by flow cytometric analysis (53.8%), 6 were 
negative (46.2%) (Table 13).  All samples resulted negative by cytology. 
Contamination with RBC was similarly present among FC+ samples and FC- 
(28.6% vs 33.3%). Median sample volume and median number of WBC/µl were 
comparable between FC+ and FC- samples. FC+ specimens showed a median 
number of events identified as blasts by flow cytometry of 92 (10-579). 
Clinical characteristics of patients who showed FC+ CSF at relapse in comparison 
with FC- are listed in Table 14. The two groups did not differ in relation to gender, 
age, blast phenotype, time to relapse, treatment protocol, HSCT donor. Among 7 
patients who were FC+ at relapse, 5 (71.4%) presented a subsequent relapse (3 
iBM, 2 iCNS), among 6 FC- patients 2 experienced a second relapse (iBM). This 
difference did not result statistically significant. There were 4 deaths in the FC+ 
group (3 disease related, 1 treatment related) and 3 deaths in the FC- group (1 
disease related, 2 treatment related), difference was not statistically significant. 
 
CSF evaluation by flow cytometry during relapse treatment  
Samples collected during relapse treatment were 96 in total. CSF specimen 
features are listed in Table 15.  Twenty samples (20.8%) were positive by FC, 75 
samples (78.1%) were negative, 1 sample resulted “uncertain”. Three FC+ 
samples showed blasts by cytology, these belonged to 2 patients who had a 
subsequent iCNS relapse. Contamination with RBC was not significantly different 
between FC+ and FC- (40% vs 26.7%) nor median CSF volume (400 µl vs 400 µl). 
Median CSF WBC count was higher in the FC+ group as compared to FC- (2/µl vs 
0/µl, p 0.002). Median number of event identified as blasts among FC+ samples 
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was 100 (range 5-32300).  
FC+ samples during treatment referred to 6 patients (5 already FC+ at relapse, 1 
FC- at relapse).  
We grouped patients on the basis of the number of samples FC+ or FC+/- from 
relapse diagnosis during the entire treatment course (Table 16). One group 
comprised patients with 2 or more FC+ (or FC+/-) samples (6 pts, 46.1%), one 
group patients with only one FC+ (or FC+/-) sample (2 pts, 15.4%) and one patients 
who were always negative by FC (5 pts, 38.5%). Statistical comparison was done 
for the two larger groups (≥2 FC+ vs FC-): these two groups did not differ in relation 
to gender, age, blast phenotype, time to relapse, treatment protocol, HSCT donor. 
The group with ≥2 FC+ showed a higher frequency of patients who were FC+ at 
relapse (83.3% vs 0%, p 0.006). Total number of subsequent relapses was higher 
among patients with more than 2 FC+ samples compared to FC- (5 vs 1, p 0.04). 
In particular, isolated CNS relapses were more frequent in the group with ≥2 FC+ 
compared to FC- (33.3% vs 0%) but the difference was not significant. Overall 
mortality and disease related mortality were also higher in the group ≥2 FC+ 
compared to FC- (66.7% and 40.0%, 50% vs 0%, respectively) but numbers were 
too low to demonstrate a statistical association.
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Tables 
 
 
Table 1: Patient characteristics grouped by CNS status at diagnosis. *negative for t(4;11), t(9;22), 
t(12;21), t(1;19). 
 
Abbreviations: CNS central nervous system, PB peripheral blood, WBC white blood cells, CSF cerebrospinal fluid, CC conventional 
cytology, FC flow cytometry, HR high risk, MR medium risk, SR standard risk, BM bone marrow. 
Patient Characteristics CNS3 CNS2 CNS1 Total 
Number of patients 5 (5.7%) 7 (8.1%) 75 (86.2%) 87 (100%) 
Gender     
Male 3 (60.0%) 5 (71.4%) 46 (61.3%) 54 (62.0%) 
Female 2 (40.0%) 2 (28.6%) 29 (38.7%) 33 (38.0%) 
Median age, range 9.9 (4.7-14.6) 5.0 (2.4-11.4) 4.5 (1.4-17.7) 4.7 (1.4-17.7) 
Immunophenotype     
pB 0 6 (85.7%) 69 (92.0%) 75 (86.2%) 
T 5 (100.0%) 1 (14.3%) 6 (8.0%) 12 (13.8%) 
Translocation     
t(12;21) 0 1 (14.3%) 18 (24.0%) 19 (21.8%) 
t(1;19) 0 0 2 (2.7%) 2 (2.3%) 
Negative* 5 (100.0%) 6 (85.7%) 55 (73.3%) 66 (75.8%) 
PB WBC at lumbar 
puncture 
    
WBC >50.000/µl 2 (40.0%) 1 (14.3%) 10 (13.3%) 13 (14.9%) 
WBC <50.000/ µl 2 (40.0%) 6 (85.7%) 65 (86.7%) 73 (83.9%) 
Not known 1 (20.0%) 0 0 1 (1.2%) 
PB blast percentage 
(median, range) 
42 (6-85) 64 (0-84) 38 (0-93) 38 (0-93) 
CSF CC at diagnosis     
CC+ 3 (60.0%) 3 (42.9%) 0 6 (6.9%) 
CC- 1 (20.0%) 4 (57.1%) 75 (100.0%) 80 (91.9%) 
Not available 1 (20.0%) 0 0 1 (1.2%) 
CSF FC at diagnosis     
FC+ 3 (60.0%) 3 (42.9%) 28 (37.3%) 34 (39.1%) 
FC- 1 (20.0%) 4 (57.1%) 45 (60.0%) 50 (57.5%) 
Not available 1 (20.0%) 0 2 (2.7%) 3 (3.4%) 
Risk group     
HR 4 (80.0%) 1 (14.3%) 20 (26.7%) 25 (28.7%) 
MR 1 (20.0%) 2 (28.6%) 41 (54.7%) 44 (50.6%) 
SR 0 4 (57.2%) 14 (18.6%) 18 (20.7%) 
Outcome     
Relapse (total) 0 0 2 (2.7%) 2 (2.3%) 
Isolated BM 0 0 2 (2.7%) 2 (2.3%) 
Isolated CNS 0 0 0 0 
Combined 0 0 0 0 
Deaths (total) 1 (20%) 0 3 (4.0%) 4 (4.5%) 
Disease related 0 0 1 (1.3%) 1 (1.1%) 
Treatment related 1 (20.0%) 0 2 (2.7%) 3 (3.4%) 
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Table 2: Statistical analysis of patient characteristics at diagnosis. Frequency were compare with 
two tailed Chi square test, median of continuous variables were compared with Mann Whitney 
Wilcoxon test.  
 
Abbreviations: CNS central nervous system, PB peripheral blood, WBC white blood cells, CSF cerebrospinal fluid, CC conventional 
cytology, FC flow cytometry, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns not significant
Patient Characteristics 
 
 p value  
(CNS3 vs CNS2+1) 
p value 
(CNS2 vs CNS3+1) 
p value 
 (CNS1 vs CNS 2+3) 
Gender (M vs F) ns ns ns 
Median age ns ns ns 
Immunophenotype (pB vs T) <0.0001 ns <0.0001 
t(12;21) vs no translocation ns ns ns 
PB WBC (>50.000/µl vs <50.000/ µl) ns ns ns 
PB blast percentage (median) ns ns ns 
CSF CC at diagnosis (CC+ vs CC-) <0.0001 0.0001 <0.0001 
CSF FC at diagnosis (FC+ vs FC-) ns ns ns 
Risk group    
HR vs MR+SR 0.03 ns ns 
MR vs HR+SR ns ns ns 
SR vs MR+HR ns 0.01 ns 
Relapse (n° relapse vs not relapsed) ns ns ns 
Deaths (n° total dead vs alive) ns ns ns 
55 
 
 
 
 
Table 3: Characteristics of CSF samples at diagnosis grouped by result of flow cytometric analysis 
(positive FC+ vs negative FC-).  
 
Abbreviations: ALL acute lymphoblastic leukemia, FC flow cytometry, RBC red blood cells, CC conventional cytology, WBC white blood 
cells,  ns not significant 
ALL at diagnosis FC+ FC- FC not 
available 
P value 
(FC+ vs FC-) 
Total 
Number of samples 34 (39.0%) 50 (57.5%) 3 (3.4%) - 87 (100%) 
Cytology      
CC+ 5 (14.7%) 1 (2.0%) 0 0.03 6 (6.9%) 
CC- 29 (85.3%) 49 (98.0%) 2 (66.6%)  80 (92.0%) 
Not available 0 0 1 (33.3%)  1 (1.1%) 
RBC Contamination       
RBC+ 15 (44.2%) 3 (6.0%) 0 <0.0001 18 (20.7%) 
RBC- 19 (55.8%) 47 (94.0%) 2 (66.6%)  68 (78.2%) 
Not available 0 0 1 (33.3%)  1 (1.1%) 
Median n° of CSF 
WBC/µl by cell count 
(range) 
1 (0-50) 0 (0-15) NA 0.04 0 (0-50) 
Median volume (µl), 
range  
450 (100-1000) 400 (100-1500) NA ns 400 (100-1500) 
Median events 
identified as blasts in 
FC (n, range) 
54 (4-3284) 0 NA - 0 (0-3284) 
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Table 4: Characteristics of patients who presented positive CSF (FC+) or negative (FC-) by flow 
cytometry at diagnosis. *negative for t(4;11), t(9;22), t(12;21), t(1;19) 
 
Abbreviations: ALL acute lymphoblastic leukemia, FC flow cytometry, PB peripheral blood, WBC white blood cells, CNS central nervous 
system, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns not significant. 
ALL at diagnosis FC+ FC– FC not 
available 
 
p value 
 (FC+ vs FC-) 
Total 
Number of patients 34 (39.0%) 50 (57.5%) 3 (3.4%)  87 (100%) 
Gender      
Male 24 (70.6%) 28 (56.0%) 2 (66.7%) ns 54 (62.0%) 
Female 10 (29.4%) 22 (44.0%) 1 (33.3%)  33 (38.0%) 
Median age, range 4.1 (1.4-17.3) 4.9 (1.8-17.6) 5.9 (2.7-17.7) ns 4.7 (1.4-17.7) 
Immunophenotype    0.02  
pB 26 (76.4%) 47 (94.0%) 2 (66.7%)  75 (86.2%) 
T 8 (23.5%) 3 (6.0%) 1 (33.3%)  12 (13.8%) 
Translocation      
t(12;21) 5 (14.7%) 14 (28.0%) 0 ns 19 (21.8%) 
t(1;19) 1 (2.9%) 1 (2.0%) 0  2 (2.3%) 
Negative* 28 (82.4%) 35 (70.0%) 3 (100.0%)  66 (75.8%) 
PB WBC at lumbar 
puncture 
   ns  
WBC >50.000/µl 8 (23.5%) 6 (12.0%) 0  53 (60.9%) 
WBC <50.000/ µl 26 (76.5%) 44 (88.0%) 2(66.7%)  33 (38.0%) 
Not known 0 0 1 (33.3%)  1 (1.1%) 
PB blast percentage 
(median, range) 
63 (4-93) 25 (0-87) 13.5 (2-25) 0.0003 43 (0-93) 
CNS status       
CNS1 28 (82.4%) 45 (90%) 2 (66.7%) ns 75 (86.2%) 
CNS2 3 (8.8%) 4 (8.0%) 0 ns 7 (8.0%)  
CNS3 3 (8.8%) 1 (2.0%) 1 (33.3%) ns 5 (5.8%) 
Risk group      
HR 14 (41.2%) 10 (20.0%) 1 (33.3%) 0.03 25 (28.7%) 
MR 9 (26.5%) 33 (66.0%) 2 (66.7%) 0.0004 44 (50.6%) 
SR 11 (32.3%) 7 (14.0%) 0 0.04 18 (20.7%) 
Outcome      
Relapse (total) 2 (5.8%) 0 0 ns (0.08) 2 (2.3%) 
Isolated BM 2 (5.8%) 0 0  2 (2.3%) 
Isolated CNS 0 0 0  0 
Combined 0 0 0  0 
Deaths (total) 3 (8.8%) 1 (2.0%) 1 (33.3%) ns  4 (4.5%) 
Disease related 1 (2.9%) 0 0 ns 1 (1.1%) 
Treatment related 1 (2.9%) 1 (2.0%) 1(33.3%) ns 3 (3.4%) 
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Table 5: Characteristics of samples of CNS1 patients grouped by flow cytometry at diagnosis. 
 
Abbreviations: CNS central nervous system, FC flow cytometry, RBC red blood cells, CSF cerebrospinal fluid, WBC white blood cells, ns 
not significant. 
 
 
Table 6: Characteristics of CNS1 patients who presented positive CSF (FC+) or negative (FC-) by 
flow cytometry at diagnosis. *negative for t(4;11), t(9;22), t(12;21), t(1;19) 
 
Abbreviations: ALL acute lymphoblastic leukemia, FC flow cytometry, PB peripheral blood, WBC white blood cells, CNS central nervous 
system, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns not significan
CNS1 at diagnosis 
 
FC+  
 
FC– 
 
p value 
(FC+ vs FC-) 
FC not 
available 
TOTAL CNS1  
 
Number of samples 28 (37.4 %) 45 (60.0%)  2 (2.7%) 75 (100%) 
RBC Contamination    0.001   
RBC+ 9 (32.1%) 2 (4.4%)  0 11 
RBC- 19 (67.9%) 43 (97.7%)  2 (100.0%) 64 
Median volume (µl), 
range  
400 (100-850) 400 (100-1500) ns NA 400 (100-1500) 
Median n° of CSF 
WBC/µl by cell count 
(range) 
0 (0-14) 0 (0-2) ns  0 (0-14) 
Median events 
identified as blasts (n, 
range) 
50 (4-2687) 0 - NA 0 (0-2687) 
CNS1 at diagnosis 
 
FC+  
 
FC– 
  
P value 
(FC+ vs FC-) 
FC not 
available 
TOTAL CNS1  
 
Number of patients 28 (37.4 %) 45 (60.0%)  2 (2.7%) 75 (100%) 
Gender   ns   
Male 20 (71.4%) 24 (53.3%)  2 (100.0%) 46 (61.3%) 
Female 8 (28.6%) 21 (46.7%)  0 29 (38.7%) 
Median age, range 4.1 (1.4-17.3) 4.7 (1.8-17.6) ns 11.5 (2.7-17.7) 4.5 (1.4-17.7) 
Immunophenotype   0.04   
pB 23 (82.1%) 44 (97.8%)  2 (100.0%) 69 (92.0%) 
T 5 (17.9%) 1 (2.2%)  0 6 (8.0%) 
Translocation      
t(12;21) 5 (17.8%) 13 (28.9%) ns 0 18 (24.0%) 
t(1;19) 1 (3.6%) 1 (2.2%)  0 2 (2.7%) 
Negative* 22 (78.6%) 31 (68.9%)  2 (100.0%) 55 (73.3%) 
PB WBC at lumbar 
puncture 
  ns   
WBC >50.000/µl 6 (21.4%) 4 (8.9%)  0 10 
WBC <50.000/ µl 22 (78.6%) 41 (91.1%)  2 (100.0%) 65 
PB blast percentage 
(median, range) 
60 (4-93) 27 (0-87) 0.001   
Risk group      
HR 11 (39.3%) 9 (20.0%) ns 0 20 (26.7%) 
MR 8 (28.6%) 31 (68.9%) 0.0008 2 (100.0%) 41 (54.7%) 
SR 9 (32.1%) 5 (11.1%) 0.02 0 14 (18.6%) 
Outcome      
Relapse (total) 2 (7,1%) 0 ns (0.07)  0 2 (2.7%) 
Isolated BM 2 (7.1%) 0  0 2 (2.7%) 
Isolated CNS 0 0  0 0 
Combined 0 0  0 0 
Deaths (total) 2 (7.1%) 1 (2.0%) ns 0 3 (4.0%) 
Disease related 1 (3.6%) 0  0 1 (1.3%) 
Treatment related 1 (3.6%) 1 (2.0%)  0 2 (2.7%) 
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Table 7: Characteristics of positive (FC+), negative (FC-) or uncertain samples (FC+/-) by flow 
cytometry during treatment 
 
Abbreviations: FC flow cytometry, RBC red blood cells, CSF cerebrospinal fluid, WBC white blood cells, ns not significant. 
 
During treatment FC+ 
 
FC– 
 
P value  
(FC+ vs 
FC-) 
FC+/- 
 
P value 
(FC+ vs 
FC+/-) 
Total 
 
Number of samples 37 (3.8%) 918 (95.1%)  11 (1.1%)  966 (100%) 
RBC contamination        
RBC+ 12 (32.4%) 287 (31.3%) ns 3 (27.3%) ns 302 (31.3%) 
RBC- 25 (67.6%) 631 (68.7%)  8 (72.7%)  664 (68.7%) 
Cytology       
CC+ 0 0 ns 0  0 
CC- 37 918  11  966 
Median volume, 
range (µl) 
450 (50-
1500) 
400 (50-1500) ns 450 (120-800) ns 400 (50-1500) 
Median n° of CSF 
WBC/µl by cell 
count (range) 
1 (0-20) 0 (0-50) 0.03 1 (0-4) ns 0 (0-50) 
Median events 
identified as blasts 
(n, range) 
17 (5-419) 0 - 7 (4-50) ns 0 (4—419) 
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Table 8: Characteristics of patients who presented positive (FC+), negative (FC-) or or uncertain 
samples (FC+/-) by flow cytometry during treatment 
 
Abbreviations: FC flow cytometry, CNS central nervous system, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns 
not significant.
During treatment At least one FC+  At least one 
FC +/-  
FC- 
 
P value 
(Fc+ vs FC-) 
Total  
 
Number of patients 19 (21.8%) 5 (5.7%) 63 (72.4%)  87 (100%) 
Gender      
Male 14 (73.7%) 2 (40.0%) 38 (60.3%) ns 54 (62.0%) 
Female 5 (26.3%) 3 (60.0%) 25 (39.7%)  33 (38.0%) 
Median age, range 5.9 (2.1-17.7) 4.6 (1.4-9.8) 4.5 (1.7-17.6) ns 4.7 (1.4-17.7) 
Immunophenotype      
pB 10 (52.6%) 4 (80.0%) 61 (96.8%) <0.0001 75 (86.2%) 
T 9 (47.4%) 1 (20.0%) 2 (3.2%)  12 (13.8%) 
Translocation      
t(12;21) 3 (15.8%) 1 (20.0%) 15 (23.8%) ns 19 (21.8%) 
t(1;19) 0 0 2 (3.2%)  2 (2.3%) 
Negative* 16 (84.2%) 4 (80.0%) 46 (73.0%)  66 (75.8%) 
CNS status at 
diagnosis 
     
CNS1 11 (57.9%) 5 (100.0%) 59 (93.7%) 0.0001 75 (86.2%) 
CNS2 3 (15.8%) 0 4 (6.3%) ns 7 (8.0%)  
CNS3 5 (26.3%) 0 0 <0.0001 5 (5.8%) 
FC at diagnosis      
FC+ 11 (57.8%) 2 (40.0%) 21 (33.3%) 0.02 34 (40.2%) 
FC- 6 (31.6%) 3 (60.0%) 41 (65.1%)  50 (56.3%) 
Not known 2 (10.5%) 0 1 (1.6%)  3 (3.4%) 
Risk group      
HR 11 (57.9%) 1 (20.0%) 13 (20.6%) 0.002 25 (28.7%) 
MR 5 (26.3%) 4 (80.0%) 35 (55.6%) 0.03 44 (50.6%) 
SR 3 (15.8%) 0 15 (23.8%) ns 18 (20.7%) 
Outcome      
Relapses (total) 1 (5.3%) 0 1 (1.5%) ns 2 (2.3%) 
Isolated BM 1 (5.3%) 0 1 (1.5%)  2 (2.3%) 
Isolated CNS 0 0 0  0 
Combined 0 0 0  0 
Deaths (total) 2 (10.5%) 0 2 (3.0%) ns 4 (4.5%) 
Disease related 0  0 1 (1.5%) ns 1 (1.1%) 
Treatment related 2 (10.5%) 0 1 (1.5%) ns 3 (3.4%) 
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Table 9: Characteristics of patients grouped by number of FC+ or FC+/- samples at diagnosis and 
during treatment.  
 
Abbreviations: FC flow cytometry, CNS central nervous system, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns 
not significant
ALL at diagnosis and 
during treatment 
≥2 FC+ or FC+/-
samples  
 
Only 1 FC+ or 
FC+/- sample  
 
FC-  
 
Total 
  
Number of patients 15 (17.2%) 28 (32.2%) 44 (50.6%) 87 (100%) 
Gender     
Male 12 (80.0%) 17 (60.7%) 25 (56.8%) 54 (62.0%) 
Female 3 (20.0%) 11 (39.3%) 19 (43.2%) 33 (38.0%) 
Median age, range 5.9 (1.4-14.6) 4.2 (1.7-17.7) 4.7 (1.8-17.6) 4.7 (1.4-17.7) 
Immunophenotype     
pB 6 (40.0%) 26 (92.9%) 43 (97.7%) 75 (86.2%) 
T 9 (60.0%) 2 (7.1%) 1 (2.3%) 12 (13.8%) 
Translocations     
t(12;21) 0 8 (28.6%) 11 (25.0%) 19 (21.8%) 
t(1;19) 0 1 (3.6%) 1 (2.3%) 2 (2.3%) 
Negative 15 (100%) 19 (67.8%) 32 (72.7%) 66 (75.8%) 
CNS status     
CNS1 9 (60.0%) 24 (85.7%) 42 (95.5%) 75 (86.2%) 
CNS2 2 (13.3%) 3 (10.7%) 2 (4.5%) 7 (8.0%)  
CNS3 4 (26.7%) 1 (3.6%) 0 5 (5.8%) 
Fc at diagnosis     
FC+ 13 (86.6%) 21 (75.0%) 0 33 (37.9%)  
FC- 1 (6.7%) 6 (21.4%) 43 (97.7%) 51 (58.6%) 
Not known 1 (6.7%) 1 (3.6%) 1 (2.3%) 3 (3.4%) 
Risk group     
HR 12 (80.0%) 4 (14.3%) 9 (20.5%) 25 (28.7%) 
MR 1 (6.7%) 14 (50.0%) 29 (65.9%) 44 (50.6%) 
SR 2 (13.3%) 10 (35.7%) 6 (13.6%) 18 (20.7%) 
Outcome     
Relapses 1 (6.7%) 1 (3.6%) 0 2 (2.3%) 
Isolated BM 1 (6.7%) 1 (3.6%) 0 2 (2.3%) 
Isolated CNS 0 0 0 0 
Combined 0 0 0 0 
Deaths 2 (13.3%) 1 (3.6%) 1 (2.3%) 4 (4.5%) 
Disease related 0 1 (3.6%) 0 1 (1.1%) 
Treatment related 2 (13.3%) 0 1 (2.3%) 3 (3.4%) 
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Table 10: Statistical analysis (Chi-square or Mann-Whitneytest) of patient characteristics 
grouped by number of FC+ or FC+/- samples at diagnosis and during treatment. 
 
Abbreviations: FC flow cytometry, CNS central nervous system, HR high risk, MR medium risk, SR standard risk, BM bone marrow, ns 
not significant
FC CSF at diagnosis and during 
treatment 
p value 
(≥2 FC+ vs 1FC+) 
p value 
(≥2 FC+ vs FC-) 
p value 
(1 FC+ vs FC-) 
Gender (M vs F) ns ns ns 
Median age ns ns ns 
Immunophenotype (pB vs T) 0.0002 0.0002 ns 
t(12;21) vs no translocation 0.02 0.002 ns 
CNS 1 vs CNS2+3 ns 0.0005 ns 
CNS2 vs CNS1+3 ns ns ns 
CNS3 vs CNS1+2 0.02 0.0004 ns 
FC at diagnosis (FC+ vs FC-) ns <0.0001 <0.0001 
HR vs MR+SR <0.0001 <0.0001 ns 
MR vs HR+SR 0.005 <0.0001 ns 
SR vs MR+HR ns ns 0.03 
Relapses (n° relapses vs not relapsed) ns ns (0.08) ns 
Deaths (n° total dead vs alive) ns ns (0.07) ns 
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Table 11: Patients with more than 2 FC+ samples are listed. First 7 columns refer to patient 
characteristics. From column 8, flow cytometric results on CSF samples are reported at different 
treatment time points.  Column 10 and 11 refer to the adjunctive lumbar puncture during IA for CNS3 
patients. Results of lumbar puncture performed during consolidation and reinduction are grouped in 
one column (15 and 16) and the number of positive samples is reported in brackets. 
 
Abbreviations: Pt patient, CNS central nervous system, IF immunophenotyped, CRT cranial radiotherapy, HSCT hematopoietic stem cell 
transplantation, diagn diagnosis, d15 day 15, IA induction IA, d 33 day 33, IB Induction IB, cons consolidation therapy, Reind Reinduction 
therapy, H high (risk), M medium, S standard, TBI total body irradiation, MUD matched unrelated donor, CR complete remission, Rel 
relapse, TR treatment related, nd not done (it was part of the treatment protocol only for CNS2 and CNS3), NA sample not available 
(patient treated in another center)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Pt  CNS 
status 
IF risk CRT HSCT outcome diagn d15 (IA)  (IA) d33 IB IB cons reind other 
1 CNS1 T H TBI MUD Alive CR + + nd nd + - - - -  
2 CNS2 pB S no No Alive CR + + - - - - - +(1) +/- (1)  
3 CNS1 pB H no No Alive CR + - nd nd - - - +/- (1) -  
4 CNS1 pB S no No Alive CR + - nd nd - - + - -  
5 CNS3 T H 18 Gy No Alive CR + + - - - - - + (1) +  
6 CNS3 T H 18 Gy  No Alive CR + + + - - - - - -  
7 CNS3 T H 18 Gy No Alive CR + + + +/- - + - - + (4) 
 
8 CNS1 pB H no No Alive CR + - nd nd - + - - -  
9 CNS1 pB H no No Alive CR + - nd nd - - - + (1) -  
10 CNS1 pB H no No Alive CR + - nd nd - - - + (1) -  
11 CNS1 pB H TBI MUD Alive CR + + nd nd - - - +/- (1) -  
12 CNS2 T H TBI MUD Alive CR - - - - + - - + (1) - +/- 
13 CNS1 T M no No Alive CR + - nd nd +/- - - - -  
14 CNS1 T H   No (dead 
before) 
No Rel, TR + - nd nd - + + + (3) -  
15 CNS3 T H TBI+ CNS 
boost 
MUD Rel, TR NA NA NA NA + - + + (2) - 
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ID gen
der 
Age at 
relapse 
(years) 
IF Time 
to 
relapse 
Genetic Second line 
treatment 
HSC
T 
FC at 
relapse 
Other 
FC+ 
(n) 
rec outcome 
1 M 11,33 pB very 
early 
no REC 2003 haplo + 5 iCNS Dead, TR 
2 F 9,50 pB late no REC 2003 MUD + 3 iBM Dead 
Progression 
3 M 9,70 pB late no REC 2003 MSD + 1 no Alive CR 
4 M 6,05 pB late t(12;21) REC 2003 MSD + 4 iBM Dead 
Progression  
5 F 4,64 pB very 
early 
no REC 2003 MUD - 0 no Dead TR 
6 F 4,85 pB late no REC 2003 MUD - 0 no Alive CR 
7 F 10,82 pB post 
HSCT 
t(9;22) personalized MSD + 5 iCNS Alive Relapse 
8 M 7,00 pB late no REC 2003 haplo - 0 iBM Dead TR 
9 M 10,45 T early FLT3ITD REC 2003 MUD + 0 iBM Alive CR 
10 M 2,74 pB very 
early 
no personalized no + 0 no Dead 
Progression 
11 M 5,12 pB very 
early 
no personalized no - 2 iBM Dead 
Progression 
12 M 12,37 pB post 
HSCT 
no personalized haplo - 0 no Alive CR 
13 F 10,24 pB late no IntReAll haplo - 0 no Alive CR 
 
Table 12: Characteristics of patients with isolated bone marrow relapse. 
Abbreviations:IF immunophenotyped, HSCT hematopoietic stem cell transplantation, M male, F female, MUD matched unrelated donor, 
MSD matched sibling donor, haplo haploidentical donor, FC flow cytometry (of CSF), iCNS isolated central nervous system, iBM isolated 
bone marrow, CR complete remission, TR treatment related. 
 
 
 
 
Table 13: Characteristics of positive (FC+), negative (FC-) or uncertain samples (FC+/-) by flow 
cytometry at iBM relapse 
 
Abbreviations: ALL acute lymphoblastic leukemia, iBM isolated bone marrow relapse, FC flow cytometry, RBC red blood cells, CSF 
cerebrospinal fluid, WBC white blood cells, ns not significant. 
ALL at iBM relapse FC+  
 
FC–  
 
 P value 
(FC+ vs FC-) 
Total  
 
Number of samples 7 (53.8%) 6 (46.2%)   13 (100%) 
RBC contamination      
RBC+ 2 (28.6%) 2 (33.3%)  ns 4 (30.8%) 
RBC- 5 (71.4%) 4 (66.7%)   9 (69.2%) 
Cytology      
CC+ 0 0  ns 0 
CC- 7 (100%) 6 (100%)   13 (100%) 
Median volume, range 
(µl) 
500 (200-800) 700 (300-1000)  ns 700 (200-1000) 
Median n° of CSF 
WBC/µl by cell count 
(range) 
1(0-4) 1.5 (0-5)  ns 1 (0-5) 
Median events 
identified as blasts (n, 
range) 
92 (10-579) 0  - 10 (0-579) 
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Table 14: Characteristics of patients who presented positive CSF (FC+) or negative (FC-) by flow 
cytometry at isolated bone marrow relapse 
 
Abbreviations: M male, F female, CT chemotheraoy, HSCT hematopoietic stem cell transplantation, MUD matched unrelated donor, MSD 
matched sibling donor, haplo haploidentical donor, FC flow cytometry (of CSF), iCNS isolated central nervous system, iBM isolated bone 
marrow, CR complete remission, TR treatment related, ns not significant.
ALL at iBM relapse FC+  
 
FC–  
 
 P value  
(FC+ vs FC-) 
Total  
 
Number of patients 7 (53.8%) 6 (46.2%)   13 (100%) 
Gender      
Male 5 (71.4%) 3 (50.0%)  ns 8 (61.5%) 
Female 2 (28.6%) 3 (50.0%)   5 (38.5%) 
Age median, range 9.7 (2.7-11.3) 6 (4.6-10.2)  ns 9.5 (2.74-12.37) 
Immunophenotype      
pB 6 (85.7%) 6 (100.0%)  ns 12 (92.3%) 
T 1 (14.3%) 0   1 (7.7%) 
Time to relapse      
Late 3 (42.8%) 3 (50.0%)  ns 6 (46.2%) 
early 1 (14.3%) 0  ns 1 (7.7%) 
Very early 2 (28.6%) 2 (33.3%)  ns 4 (30.8%) 
Post HSCT 1 (14.3%) 1 (16.7%)  ns 2 (15.4%) 
Protocol of CT      
ALL-REC 2003 5 (71.4%) 3 (50.0%)  ns 8 (61.5%) 
IntReALL-SR 0 1 (16.7%)  ns 1 (7.7%) 
personalized 2 (28.6%) 2 (33.3%)  ns 4 (30.8%) 
HSCT      
MFD 3 (42.8%) 0  ns 3 (23.1%) 
MUD 2 (28.6%) 2 (33.3%)  ns 4 (30.8%) 
Haplo 1 (14.3%) 3 (50.0%)  ns 4 (30.8%) 
No HSCT 1 (14.3%) 1 (16.7%)  ns 2 (15.3%) 
Outcome      
Second Relapse (Total) 5 (71.4%) 2 (33.3%)  ns 7 53.8%) 
iBM 3 (42.8%) 2 (33.3%)  ns 5 (38.5%) 
iCNS 2 (28.6%) 0  ns 2 (15.4%) 
combined 0 0    
Deaths (total) 4 (57.2%) 3 (50.0%)  ns 7 (53.8%) 
Disease related 3 (42.8%) 1 (16.7%)  ns 4 (30.8%) 
Treatment related 1 (14.3%) 2 (33.3%)  ns 3 (23.1%) 
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Table 15: Characteristics of positive (FC+), negative (FC-) or uncertain samples (FC+/-) by flow 
cytometry during treatment of iBM ALL relapse.  
 
Abbreviations: ALL acute lymphoblastic leukemia, iBM isolated bone marrow relapse, FC flow cytometry, RBC red blood cells, CSF 
cerebrospinal fluid, WBC white blood cells, ns not significant
CSF during relapse 
treatment 
FC+ 
 
FC– 
 
p value 
(FC+ vs FC- ) 
FC+/-  
 
Total   
 
Number of samples 20 (20.8%) 75 (78.1%)  1 (1%) 96 (100%) 
Cytology      
CC+ 3 (15.0%) 0 0.0007 0 3 (3.1%) 
CC- 17 (85.0%) 75 (100%)  1 (100%) 93 (96.9%) 
RBC contamination       
RBC+ 8 (40.0%) 20 (26.7%) ns 0 28 (28.6%) 
RBC- 12 (60.0%) 55 (73.3%)  1 (100%) 68 (71.4%) 
Median volume, range 
(µl) 
400 (100-
1200) 
400 (100-1500) ns 500 400 (100-1500) 
Median n° of WBC/µl 
by cell count (range) 
2 (0-214) 0 (0-14) 0.002 0 (0-1) 1 (0-214) 
Median events 
identified as blasts (n, 
range) 
100 (5-
32300) 
0 - 10 (21-7) 0 (0-32300) 
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Table 16: Characteristics of patients grouped by number of FC+ or FC+/- samples at 
relapse and during relapse treatment.  
 
Abbreviations: M male, F female, FC flow cytometry, CT chemotherapy, HSCT hematopoietic stem cell transplantation, 
MUD matched unrelated donor, MSD matched sibling donor, haplo haploidentical donor, FC flow cytometry (of CSF), iCNS 
isolated central nervous system, iBM isolated bone marrow, CR complete remission, TR treatment related, ns not significant. 
 
 
 
 
 
 
CSF at relapse and 
during treatment 
≥2 FC+ or 
FC+/-  
 
Only 1 FC+ or 
FC+/-  
 
FC–  
 
P value  
(>2 FC+ 
vs FC-) 
 
Total  
 
Number of patients 6 (46.1%) 2 (15.4%) 5 (38.5%)  13 (100%) 
Gender      
Male 4 (66.7%) 2 (100.0%) 2 (40.0%) ns 8 (61.5%) 
Female 2 (33.3%) 0  3 (60.0%)  5 (38.5%) 
Median age, range 9.6 (5.1-11.3) 6.5 (2.7-10.4) 7.0 (4.6-12.3) ns 9.5 (2.74-12.37) 
Immunophenotype      
pB 6 (100.0%) 1 (50.0%) 5 (100.0%) ns 12 (92.3%) 
T 0  1 (50.0%) 0  1 (7.7%) 
FC at relapse      
FC+ 5 (83.3%) 1 (50.0%) 0 0.006 6 (46.2%) 
FC- 1 (16.7%) 1 (50.0%) 5 (100%)  7 (53.8%) 
Time to relapse      
Late 3 (50.0%) 0 3 (60.0%) ns 6 (46.2%) 
Early 0  1 (50.%) 0 ns 1 (7.7%) 
Very early 2 (33.3%) 1 (50.0%) 1 (20.0%) ns 4 (30.8%) 
Post HSCT 1 (16.7%) 0 1 (20.0%) ns 2 (15.4%) 
Protocol of CT      
ALL-REC 2003 4 (66.6%) 0 3 (60.0%) ns 7 (53.8%) 
IntReALL-SR 0 0 1 (20.0%) ns 1 (7.7%) 
personalized 2 (33.3%) 2 (100.0%) 1 (20.0%) ns 5 (38.5%) 
HSCT      
MFD 3 (50.0%) 0 0 ns 3 (23.1%) 
MUD 1 (16.7%) 1 (50.0%) 3 (60.0%)  5 (38.5%) 
Haplo 1 (16.7%) 0 2 (40.0%)  3 (23.0%) 
No HSCT 1 (16.7%) 1 (50.0%) 0  2 (15.4%) 
Outcome      
Relapses (total) 5 (83.3%) 1 (50%) 1(20.0%) 0.04 7 (53.8%) 
iBM 3 (50.0%) 1 (50.0%) 1(20.0%) ns 5 (38.5%) 
iCNS 2 (33.3%) 0 0 ns 2 (15.4%) 
combined 0 0 0  0 
Deaths (total) 4 (66.7%) 1 (50%) 2 (40.0%) ns 7 (53.8%) 
Disease related 3 (50.0%) 1 (50.0%) 0 ns 4 (30.8%) 
Treatment related 1 (16.7%) 0 2 (40.0%) ns 3 (23.1%) 
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Discussion 
 
Despite the great advances in the cure of ALL, relapses still occur in approximately 15-
20% of patients. Relapses involving the CNS account for up to 40% of all relapses, 
as apposite to 5% CNS involvement at diagnosis (59). Factors associated with 
augmented risk of CNS relapse are: the presence of blasts in the cerebrospinal 
fluid at diagnosis, T-ALL phenotype, hyperleukocytosis and high risk translocations 
such as t(9;22) and t(4;11) (35). 
Prophylaxis and therapy directed to the CNS include intrathecal administration of 
chemotherapy and cranial irradiation. In case of HSCT, total body irradiation (TBI) 
combined to a radiotherapy boost to cranium and, in some cases, spine, are used 
to completely eradicate meningeal leukemia in patients at risk. CRT increases the 
risk of secondary neoplasms (especially CNS neoplasms), neurocognitive and 
endocrine dysfunctions and growth impairment (35). Therefore, most recent trials 
have omitted radiotherapy form first line therapy of ALL (14).   
Even an intrathecal chemotherapy approach is not without adverse events 
including post-dural puncture headache, CNS hemorrhage, leukoencephalopathy, 
chemical meningitides and spinal cord dysfunction (35). Moreover, it is reported 
that patients who underwent CNS prophylaxis with IT therapy only had also some 
neurocognitive deficit in the area of attention and memory (10,11).  
In order to define which patients may benefit of a less toxic treatment or, on the 
contrary, may have a high risk of CNS relapse therefore requiring specific 
intervention, it is essential to identify reliable risk factors. 
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Current definition of CNS involvement in asymptomatic patients requires a positive 
cytology with cell count over a certain threshold and/or a positive neuroimaging.  
Sensitivity and, in some cases, also specificity of cytology has been proven low. 
Limitations to cytological diagnosis include: the small sample volume and the 
paucity of cellular material, the need to process the sample quickly to prevent cell 
degeneration and the possible difficulty in distinguish blasts from normal 
lymphocytes or monocytes. Flow cytometry has been used to analyze CSF 
samples, showing high sensitivity even in samples with low cellularity. Moreover, it 
can help in identifying blasts from normal cells, thus improving CC specificity 
(16,17). Cell degradation can be prevented by the use of fixative before FC 
analysis (18,45,55).   
Studies on adult patients with lymphoma or leukemia reported a higher prevalence 
of CSF positivity by FC in comparison to cytology (44, 45, 47, 48). Moreover, 
prospective studies on patients affected by aggressive B non-Hodgkin lymphoma 
(NHL) reported an inferior outcome and a higher frequency of CNS relapses in 
patients who presented blasts in CSF by flow cytometry (46-48). 
In pediatric ALL, CNS involvement detected by FC but not by standard CC has 
been found in around 30% of children at primary diagnosis (49, 55, 57). Clinical 
significance in children with ALL is less clear: four papers until now had addressed 
this topic. 
A retrospective study published in 2015 reported the results in a group of 302 
children with ALL diagnosed from 2000 to 2012. CSF samples were studied at 
diagnosis by FC (from three to eight colors). Treatment protocols and risk 
stratification were heterogeneous: patients were treated according to NOPHO 
ALL1992, ALL2000, ALL2008, Interfant99 or Interfant06. FC positivity was found 
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in 4% of children, in this group a higher frequency of high risk patients was 
observed. Patients with FC+ sample at diagnosis had a higher incidence of relapse 
compared to FC- but the small numbers did not allow a statistical comparison (50). 
In a Spanish multicenter study, 108 children (0-15 years) were included and CSF 
was analyzed prospectively at diagnosis and during treatment (in total 990 
samples, traumatic lumbar punctures were excluded). Patients were treated 
according to two chemotherapy protocol (SHOP or PETHEMA), median follow up 
was 35 months. Five colors-FC resulted positive in 27.8% samples a diagnosis and 
in 7.2% during treatment. The presence of FC+ was associated with other poor 
prognostic features such as high WBC counts, HR classification, T-ALL, MLL 
rearrangement and t(9;22) translocation. CSF positivity by FC during treatment, 
but not at diagnosis, was associated to a higher incidence of relapses and a higher 
mortality. Multivariable analysis, however, was not performed in order to rule out 
the impact of high risk factors on the inferior outcome of FC+ patients (55). 
A Chinese prospective single center’s study analyzed 313 children (2-14 years) 
with ALL treated uniformly with a chemotherapy protocol not including CRT. Infant 
cases and children with t(9;22) were included. Seventy-nine patients presented 
FC+ samples by 3 colors-FC (13 at presentation and 66 during therapy), they were 
randomly allocated to standard treatment or to enhanced IT therapy. The latter 
group showed a better OS (80% vs 50%) and a lower incidence of CNS relapse 
(30% vs 10%). A multivariable analysis was not performed. However, these results 
can be difficultly compared to other works, as treatment protocol, access to care, 
and subsequently, relapse and mortality rates are very different from that area in 
China to Western countries (56). 
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Finally, a paper published last year by NOPHO (Nordic Society of Pediatric 
Hematology and Oncology) reported results obtained by 6-7 colors-FC on a cohort 
of 300 children affected by ALL and 9 relapsed cases. Patients were treated 
according to Interfant-06 (if younger than 1 year), EsPhALL (if Philadelphia 
positive) or NOPHO ALL2008. FC found blasts at diagnosis in 29% of children, 
these patients were more frequently T-ALL, younger and with high WBC count on 
peripheral blood. Among 9 relapsed patients 56% were FC+, but nor CC results, 
nor clinical characteristics or outcome were reported for this group. Among FC+ 
patients at diagnosis, 10% of them were still positive at day 15, subsequent 
samples were not analyzed. The clinical significance of these findings could not be 
ruled out by this study (57).  
Given that the clinical significance of CSF involvement detected by flow cytometry 
is not clear in children with ALL and relapsed ALL, we performed a prospective 
single-center study from 2013 to 2016. One thousand and one hundred sixty-one 
CSF samples, at each lumbar puncture during therapy in primary and relapsed 
ALL, were analyzed by FC and compared to cytology and cell count; prognostic 
value of FC analysis was studied. 
A number of aspects made this study different from the previous ones. Collected 
CSF samples were processed directly for FC without the addiction of any 
preservative or fixative, to exclude the possibility that this could alter final results. 
This was possible because the work was carried out at a single institution and the 
samples could be analyzed within 24 hours. It is important, as we did, that all the 
samples were handled in the same way. Notably, in our hand, samples were still 
evaluable by FC at least until 24 hours from collection.  
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For this study we used 8-colors flow cytometry, thus allowing a complete analysis 
in a single tube with less CSF volume requirement. Moreover, the higher number 
of antigen analyzed (as compared to other pediatric studies) improves the 
specificity of the analysis. Differently to other studies (45, 52, 54), that used 10 to 
20 events as an arbitrary cut off value, we did not set a threshold to define the 
positivity of a sample by FC, because we choose not to exclude any finding from 
the analysis based on arbitrary rules. For the same reason, we decided not to 
exclude samples possibly contaminated by peripheral blood. Nevertheless, the 
percentage of FC+ at diagnosis in our cohort was comparable to another published 
report (55).  
RBC contamination was higher in the FC+ group at diagnosis compared to FC- 
(44% vs 6%, p<0.0001), suggesting that samples resulted positive by FC because 
of PB contamination. Nevertheless, 56% of FC+ samples were negative for RBC. 
Moreover, even if blasts detected by FC could have been of PB origin, we thought 
that their presence in CSF could be a potential risk factor for subsequent CNS 
relapse. Therefore, we decided not to exclude those samples from the analysis. 
During treatment, there was no difference in terms of RBC contamination between 
FC+ and FC- samples. Results were not influenced by sample volume, as no 
difference in median volume was evident between FC+ and FC- specimens at 
diagnosis and during treatment. 
Both PB contaminated or no-contaminated samples contained T lymphocytes, and 
a small proportion monocytes and B lymphocytes. This finding is not reported by 
studies on pediatric ALL, but it is in line with adult reports (15, 45). 
Cytological analysis resulted less sensible than flow cytometry in detecting blasts, 
as reported by other authors (16-18,45): in total 29/87 (33.3%) samples were 
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negative by CC but positive by FC. This frequency is comparable to the study by 
Martinez-Laperche et al (55) who found 25% of samples positive by FC only. One 
case resulted CC+ but FC-: flow cytometry showed normal B and T lymphocytes 
that were possibly interpreted as blasts by morphologist. 
Regarding clinical characteristics, patients with FC+ at diagnosis had mainly T-
ALL, higher peripheral blast percentage and high-risk features. The same was also 
observed by the works of Martinez-Laperche and Levinsen (55,57), with the 
exception that they found a higher peripheral WBC count among FC+ patients. In 
our study, in the CNS1 group, significant differences between FC+ and FC- at 
diagnosis remained phenotype and PB blast percentage. 
FC+ patients at diagnosis showed a trend towards an inferior outcome: more BM 
relapses and deaths were found in FC+ group compared to FC-, but the difference 
did not result statistically significant. Moreover, due to the low numbers of relapsed 
patients, a survival analysis nor a multivariable analysis were performed. These 
results are in line with the work by Ranta et al (50), that, retrospectively, found a 
higher number of relapses among FC+ patients at diagnosis without statistical 
significance, and with Martinez-Laperche et al (55) who did not find any difference 
in outcome based on FC results at diagnosis. Our data are in contrast with those 
reported by Liang et al (56), who found more CNS relapses among FC+ patients. 
Since the incidence of relapses is relatively low in pediatric ALL, the total number 
of patients and the length of follow up of our work may have been too small to 
detect any statistical difference between FC+ and FC- patients. As a 
demonstration, when children were treated with less intensive protocols, as in the 
Chinese study, FC detection of blasts in CSF was predictive of CNS relapse. 
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Moreover, our cohort did not include patients with t(9;22) translocation nor infant 
ALL patients, both categories having a higher risk of CNS relapse (35). 
We then analyzed separately CSF samples obtained during ALL treatment. As 
mentioned in the results, RBC contamination and volume were homogenously 
distribute between FC+ and FC- samples, CSF WBC count was higher among 
FC+. Like at diagnosis, FC+ patients during treatment were mainly T-ALL, CNS3 
and HR. The same characteristics were reported by Martinez-Laperche et al when 
they analyzed the group with FC+ during treatment (55). Differently to their work, 
our study did not find any outcome difference for this subgroup of patients. Even 
considering patients with more than 2 FC+ samples at diagnosis and during 
treatment, we could not demonstrate an augmented risk of relapse or death. 
Looking at Table 11, where characteristics of patients having more than 2 FC+ 
samples are reported, it appears that patients having T-ALL, CNS3 and/or HR 
features are prone to have occult CNS involvement at diagnosis and at different 
time points during treatment. Nevertheless, they do not exhibit overt CNS leukemia 
probably thanks to intensive treatment that it is already administered to these 
categories, including RCT in CNS3 and T-HR patients. 
 
Regarding patients with iBM ALL relapse, FC found blasts in CSF at presentation 
in 53.8% of patients, similarly to that reported by Levinsen et al (57). 
In our cohort of relapsed ALL, FC+ samples were not associated to higher RBC 
contamination, CSF WBC count or sample volume compared to FC-. Patient 
characteristics and outcome did not differ in relation to FC results at relapse 
presentation.  
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Five out of six patients who presented FC+ at relapse, had other FC+ samples 
during relapse treatment. One patient was negative at relapse but showed other 
FC+ samples during the course of therapy. Five out of 6 patients with more than 2 
FC+ samples presented a subsequent relapse and 4/5 died (one is still alive but 
not in CR). Relapse incidence resulted higher for this group of children compared 
to FC-, mortality showed the same trend but without statistical significance. The 2 
CNS relapses were confined to the group of patients FC+, but we could not 
demonstrate a statistical association. Notably, phenotype, time to relapse, type of 
treatment and HSCT did not differ between the two groups (≥2 FC+ vs FC-). Due 
to the low number of patients, it was not possible to perform a survival curve or a 
multivariable analysis. Nevertheless, we think that these results are important for 
several reasons. First, because this is the first report that prospectively evaluated 
FC analysis on CSF of children with relapsed ALL. Second, our observation 
reinforces the concept, suggested by the study of Hagedorn who found 
submicroscopic BM involvement in the majority of isolated extramedullary relapse 
(60), that most ALL relapses have a systemic rather than an isolated recurrence. 
The persistent presence of blasts in CSF may reflect either an occult CNS 
involvement not sufficiently treated (because not apparent by CC) or a resistant 
BM disease that constantly spreads to CNS. The two patients who developed a 
CNS relapse probably had an occult CNS involvement that was not adequately 
treated by systemic chemotherapy. Persistent CSF positivity may also be a signal 
of a more aggressive disease. 
 
Our study was limited by the small patient sample size, especially of relapsed ALL, 
and by the relatively short follow up. A multicenter study and a longer follow up 
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may overcome these limitations. However, the single-center approach permitted 
us to analyze specimens without fixation and to collect precise clinical data. 
Moreover, the number of CSF samples we analyzed was larger than published, 
reaching the total of 1159 samples.  
Another possible limitation is that we did not establish a threshold to define CSF 
positivity by FC, neither we were able to calculate blast load in CSF samples. Given 
the fact that CSF is usually hypocellular, we think that is not correct to report blast 
quantity as a percentage, as it is usually done on marrow and blood samples. 
Quantification of leukemic cells in CSF should be done precisely with counting 
beads, a method already reported on CSF samples (15, 45). As current available 
literature is based only on a qualitative assessment of CSF by FC, our results are 
at least comparable to those published.   
  
In conclusion, our data demonstrated that FC analysis of ALL CSF samples is 
feasible; CNS involvement by FC is a frequent finding in pediatric ALL at diagnosis 
and, even more, at relapse. The clinical significance is probably linked to the 
persistence of CSF positivity rather than to the single sample analysis. Actual 
frontline treatment protocols seem to be able to control CNS submicroscopic 
leukemia, although a longer follow up is needed to confirm this finding.  In relapsed 
ALL patients, persistent CSF positivity may be a sign of a more resistant disease 
and a prognostic negative factor. A larger group of patients has to be studied in 
order to verify our observations.  
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Hematopoietic Stem Cell Transplantation for Isolated 
Extramedullary Relapse of Acute Lymphoblastic 
Leukemia in Children  
 
 
Abstract 
Relapse of Acute Lymphoblastic Leukemia (ALL) may occur in extramedullary 
sites, mainly the central nervous system (CNS) and the testis. Optimal post-
remissional treatment for isolated extramedullary relapse (IEMR) is still 
controversial. To address this issue, we collected data of patients treated with 
hematopoietic stem cell transplantation (HSCT) for ALL IEMR. From 1990 to 
2015, 281 children underwent HSCT for ALL IEMR in Italy. Pre-transplant 
treatment protocols were based on Berlin-Frankfurt-Münster (BFM) Study 
Group backbone. HSCT was performed in second complete remission (CR2) 
or subsequent remission (CR>2); also patients transplanted with active disease 
were included in the analysis. HSCT from an HLA-matched donor was 
performed whenever a matched family (MFD) or a matched unrelated donor 
(MUD) was available; otherwise, the single center chose to perform either 
autologous HSCT (auto HSCT) or HLA-haploidentical HSCT (haplo HSCT). 
Of the 281 patients (203 male, 78 female) 167 presented relapse confined to 
CNS, 73 to testis, 14 to mediastinum, 11 to CNS and other sites and 18 to other 
organs. Ninety-seven patients underwent auto HSCT, 79 MFD HSCT, 75 MUD 
HSCT and 30 haplo HSCT. At transplantation, 72.6% of children were in CR2, 
21.0% in CR>2 and 6.4% were not in remission. Overall survival (OS) for the 
entire cohort was 56% at 10 years and was not influenced by gender, ALL blast 
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immune-phenotype, age, site of relapse, duration of first remission, type of 
HSCT (auto vs MFD vs MUD vs haplo). In multivariable analysis, the only 
factors influencing outcome were disease status at time of HSCT and year of 
transplantation. Patients in CR>2 had a risk of death 2.3 times greater than 
those in CR2. Children treated after 2000 had half the risk of death than those 
treated before that year.  
Our results suggest that both autologous and allogeneic HSCT are a suitable 
treatment for ALL IEMR.  
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Introduction  
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. 
Although current treatments are able to cure up to 85% of children, relapse is the 
leading cause of treatment failure, affecting approximately 15-20% of patients. 
Leukemia relapse most frequently involves the bone marrow (BM), but it can occur 
in extramedullary sites, mainly the central nervous system (CNS) and the testis, 
either alone or in combination with BM relapse [1]. 
Site of relapse and duration of first remission are the most important prognostic 
factors, early and isolated BM relapse predicting the worst outcome [2, 3]. While 
the benefit of allogeneic hematopoietic stem cell transplantation (allo HSCT) has 
been demonstrated for high-risk relapsed patients, optimal post-remissional 
treatment for low-risk relapsed patients is still controversial [4-8]. Our previous 
works [9, 10] demonstrated that autologous HSCT (auto HSCT) may be a good 
curative option for children experiencing isolated extramedullary relapse (IEMR). 
For further addressing this issue, we collected and analyzed data of a large cohort 
of patients with first or subsequent ALL IEMR: 281 children with IEMR were treated 
with either auto HSCT or allo HSCT over a 25 years period (1990-2015) in Italy. 
To the best of our knowledge, this is the largest study that uniformly analyzes the 
outcome of this subgroup of patients.
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Patients and Methods 
This is a retrospective multicenter study involving 20 Italian centers, members of 
the Italian Pediatric Onco-Hematology Association (AIEOP) network. 
Data were extracted from the AIEOP-Stem Cell Transplantation (AIEOP-SCT) 
Registry. We included children (age 1-18 years) with IEMR of ALL who underwent 
HSCT between 1st of January 1990 and 31st December 2015. Written informed 
consent was obtained from parents or legal guardians. 
Patients’ characteristics are shown in Table 1. IEMR was defined as presence of 
leukemia blasts in extramedullary sites with <5% blasts in BM. CNS relapse was 
defined as presence of >5 cell/µL in the cerebrospinal fluid (CSF) and detection of 
lymphoblasts by examination of CSF cytocentrifugate. Alternatively, clinical signs 
of cranial nerves involvement or radiologic signs at cerebral magnetic resonance 
imaging/ computed tomography (MRI/CT) were considered diagnostic of CNS 
relapse. Relapse involving testis or other organs was confirmed by biopsy. 
“Very early” relapse was defined as disease recurrence occurring less than 18 
months from primary diagnosis, “early” relapse if it occurred later than 18 months 
from diagnosis and less than 6 months from treatment discontinuation, “late” 
relapse if it occurred more than 6 months from treatment discontinuation [3]. 
At diagnosis and relapse, patients were treated according to national protocols 
available at that time, based on Berlin-Frankfurt-Münster (BFM) Study Group 
backbone.  
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HSCT was mainly performed in second or subsequent complete remission (CR); 
patients transplanted with active disease were also included in the study. If a HLA-
matched family donor (MFD) or a matched unrelated (MUD) donor was available, 
allo HSCT was performed; if not, the decision to proceed with either auto HSCT or 
haploidentical HSCT (haplo HSCT) was taken by the single center. 
Conditioning regimen mainly included 12 Gy total body irradiation (TBI), details on 
conditioning regimens are listed in Table 2. 
 
Statistical analysis 
Data were extracted from the AIEOP-SCT Registry on the 28th of February, 2016.  
Overall Survival (OS) was defined as the time from transplantation to last follow-
up or death due to any cause. Disease free survival (DFS) was defined as the time 
from transplantation to disease recurrence or death from any case. Relapse free 
survival (RFS) was defined as the time from transplantation to documented relapse 
of ALL for patients transplanted in CR, for the purpose of this study RFS was 
calculated in the group of patient with CR2CI of treatment-related mortality (TRM) 
was defined as the time from transplantation to death from causes other than 
disease recurrence/progression, taking into account relapse as competing event. 
OS, DFS, and RFS were calculated at 10 years using the Kaplan-Meier method 
with 95% confidence interval. Difference in survival was estimated with the log-
rank test.  
Cumulative incidence of TRM was evaluated at 100 days, 6 months, 1 year and 10 
years from transplantation. Incidence curves were compared with Gray’s test. In 
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multivariable Cox regression analysis, factors with a p-value <0.2 were included. 
The risk of death was expressed as the hazard ratio (HR) with 95% confidence 
interval. Differences in the distribution of various parameters were compared using 
chi-square or Fisher exact test as appropriate. A p-value <0.05 was considered to 
be statistically significant. 
Analysis was performed with SAS software (SASPC, version 9.3, SAS Institute, 
Cary, NC).  
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Results 
Patient characteristics 
Two hundred and ninety-two patients underwent HSCT for IEMR from 1st January 
1990 to 31st December 2015. Two hundred and eighty-one (203 male, 78 female) 
patients were included in this study, 11 patients were excluded because of 
insufficient data. Median age at diagnosis was 5.5 years (range 0.3 – 18), while 
median age at relapse was 7.7 years (range 1.1 – 20.5).  
Relapse was confined to CNS in 167 patients (59.4%), to testis in 73 patients 
(26.0%), to mediastinum in 14 patients (5.0%), to CNS and other sites in 11 
patients (3.9%) and to other sites in 16 patients (5.7%). These sites comprised: 
eye in 4 patients, lymph nodes in 3 patients and still others (eye and skin, skin, 
abdomen, retroperitoneum, kidney, liver, pelvis, ovary and soft tissue) in 1 patient 
each. Characteristics of patients are listed in Table I. 
TBI was part of the preparative regimen 93.2% of cases (details are given in Table 
II). Data regarding additional radiotherapy are known only for 93 patients: 10 out 
of 93 received a radiotherapy boost to the site of relapse at time of TBI.  
Gender, age, site of relapse and TBI containing regimens were uniformly 
distributed among HSCT types (p>0.05). ALL blast immune-phenotype, remission 
status at transplantation, duration of first CR, source of stem cells and year of 
transplantation were not uniformly distributed; in particular, patients with T-ALL 
were treated more frequently with either MUD or haplo HSCT (p 0.0028). Likewise, 
very early relapses were mainly treated with MUD HSCT (p 0.0043) and patients 
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with CR greater than 2nd were more frequent in the haplo HSCT group (p 0.0031) 
(Table I). 
Mean follow up from transplantation was 5.9 years (range 0.01-26 years, median 
2.8 years). During this period, 81 patients experienced a second relapse or disease 
progression at a median time of 176 days (range 15-2345) from HSCT: 48 marrow 
isolated, 16 extramedullary isolated, 7 combined, 10 unknown site. One hundred 
and fourteen patients died at a median time of 241.5 days (range 12-6623) from 
HSCT: 61 for relapse, 46 for treatment-related complications, 4 for a second tumor, 
3 for an unknown event. In particular, mortality for a second malignancy occurred 
at a median time of 3117 days (range 88-6623). Acute GVHD (aGVHD) (grade II-
IV) occurred in 79 (42.9%) of 184 patients who received an allograft, while chronic 
GVHD (cGVHD) was diagnosed in 32 out of 151 patients alive at days +100 
(21.2%).  
 
Overall survival 
The overall survival for the entire cohort was 56% at 10 years (SE ± 3%) and was 
not influenced by gender, ALL blast immune-phenotype (B-cell precursor, Bcp-, vs 
T-ALL), age (≤10 years vs >10 years). As per site of relapse, OS was slightly better 
for patients with isolated testicular relapse (OS 66% at 10 years, SE ± 6%) as 
compared to patients with CNS relapse alone (OS 53%, SE ± 4%), CNS and other 
sites (OS 55% SE ± 15%), mediastinum (OS 39% SE ± 14%) and other organs 
(OS 62% SE ± 13%), but this difference is not statistically significant (p 0.22). 
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The length of first CR was not associated with a better survival, as the 10-year OS 
for very early, early and late IEMR was 52%± 6%, 53% ± 5%, and 61%± 6% 
respectively (p 0.39). 
Comparison between auto and allo HSCT did not show any difference in terms of 
OS at 10 years (57% ± 5% vs 56% ± 4%, p 0.53). No statistically significant 
difference was also observed if different type of HSCT were compared: OS for auto 
HSCT, MFD, MUD and haplo HSCT was 57% ± 5, 56% ± 6%, 62% ± 6%, and 46% 
±10%, respectively (p 0.09) (Figure I). The source of stem cells (peripheral blood, 
bone marrow or cord blood) did not affect OS, as well. 
TBI-containing regimen yielded a better OS (59%) compared with conditioning 
without TBI (40%) but this difference was not statistically significant (p 0.069). 
In univariable analysis, the only prognostic factors associated with OS in our cohort 
were: remission status at transplantation (CR2, CR>2 or presence of disease) and 
the year in which patients were treated (either before or after the year 2000). 
Patients transplanted in CR2 had the better OS at 10 years (64%± 4%); those given 
HSCT in subsequent CR showed an OS of 44%± 7%, while patients transplanted 
with active disease had an OS of only 11%± 7% (p<0.0001) (Figure II). For HSCT 
performed before the year 2000 the OS was 45% ± 5% at 10 years, while for those 
performed after 2000 was it was 63% ± 4% (p=0.0009).  
 
Disease free survival  
Global DFS was 54% at 10 years (SE ±3%); DFS did not differ in relation to gender, 
ALL blast immune-phenotype (pB- vs T-ALL), age (≤10 years vs >10 years). 
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Regarding the site of relapse, DFS at 10 years was 65% (± 6%) for testicular 
relapse, 49% (± 4%) for CNS relapse, 55% (± 15%) for CNS relapse together with 
other sites, 40% (± 14%) for mediastinal relapse and 65% (± 13%) for other sites 
involvement (p 0.22). As for OS, in our cohort DFS was not influenced by the 
duration of first CR: at 10 years, it was 52% (± 6%) for very early relapse, 53% (± 
5%) for early relapse and 58% (± 6%) for late relapse (p 0.55). 
Auto and allo HSCT had very similar DFS at 10 years (54% ±5% vs 55% ±,4% p 
0.66), DFS was 55% ± 6% for MFD, 59% ± 6% for MUD, 47% ± 10% for haplo 
HSCT. The source of stem cells (peripheral blood, bone marrow or cord blood) did 
not affect RFS. The only factors statistically significant for DFS were: presence of 
TBI in conditioning regimen, remission status at HSCT and year of transplantation. 
TBI-containing regimens were associated with a better DFS at 10 years as 
compared to non-TBI containing regimens (58% ± 4% vs 37% ± 8%, p 0.008). 
Remission status at HSCT strongly correlated with DFS: patients transplanted in 
CR2 had a better DFS (63%±4%) in comparison to those transplanted in CR>2 
(39% ±7%) or not in remission (11%±7%) (p<0.0001). 
DFS for patients transplanted before and after 2000 was 45%± 5% and 61%± 4%, 
respectively (p 0.0008).  
 
Transplant-Related Mortality 
TRM for the entire cohort was 10% ± 2% at 100 days, 11% ± 2% at 6 months and 
1 year and 16% ± 2% at 10 years. TRM for auto HSCT was 4% ± 2%, 6% v 2%, 
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6% ± 2%, and 11% ± 3%, while TRM for allo HSCT (MUD, MFD and haplo HSCT) 
was 13% ± 2%, 14% ± 3%, 14% ± 3%, and 18% ± 3% at 100 days, 6 months, 1 
year and 10 years, respectively. 
 
Subgroup analysis and multivariable analysis 
As length of CR1 is one of the most important prognostic factors in relapsed ALL, 
we performed separate analyses for patients with very early, early and late IEMR.  
Regarding very early relapse (n= 87) curves of DFS and OS at 10 years showed a 
trend in favor of allogeneic HSCT versus autologous HSCT (58% ± 6% vs 44% ± 
12% and 59% ± 6%  vs 44% ± 12%, p 0.28 and 0.29 respectively). In early relapsed 
patients (n=97), DFS and OS at 10 years were comparable irrespectively whether 
patients were treated with either auto or allo HSCT (55% ± 9% vs 50 ± 7%, p 0.88 
and 54% ± 9% vs 52%, ± 7% p 0.87). If only patients with late relapse were 
considered (n= 87), DFS and OS at 10 years showed slightly better values with 
auto HSCT in comparison with allo HSCT (MFD, MUD and haplo combined): 65% 
± 8% vs 48% ± 9% and 68% ± 7% vs 52% ± 9%, respectively, the differences were 
not statistically significant (p 0.13 and p 0.12). Curves of OS are shown in Figure 
III. 
Remission status at transplantation is well known to influence outcome, so we 
conducted a separate analysis for patients in CR2 at time of HSCT (n=204). RFS 
and OS for the entire cohort were 74% ± 3% and 64% ± 3%, respectively; outcome 
of patients given either autologous HSCT or allogeneic HSCT was similar (RFS for 
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auto HSCT 70% ± 5% vs 78% ± 4% for allo HSCT p 0.37; OS for auto HSCT 67% 
± 5% vs 64% ± 5% for allo HSCT p 0.84).  
 
Multivariable analysis was conducted after adjustment for remission status: 
patients with active disease at transplantation were excluded from the analysis due 
to the high incidence of treatment failure in this group. As shown in Table III, in 
multivariable analysis the only factors influencing OS in patients with IEMR treated 
with HSCT were number of relapses and year of transplantation. Patients 
experiencing more than one relapse have a risk of death 2.3 times greater than 
patient transplanted in CR2; children treated with HSCT after 2000 have half the 
risk of death than those treated from 1995 to 2000.  
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 AUTO-
HSCT 
(n=97) 
MFD-
HSCT 
(n=79) 
MUD-
HSCT 
(n=75) 
Haplo-
HSCT 
(n=30) 
total of 
patients 
(n=281) 
 
Gender           p 0.8308 
Male 67 (69.1%) 58 (73.4%) 55 (73.3%) 23 (76.7%) 203 (72.3%)  
Female 30 (30.9%) 21 (26.6%) 20 (26.7%) 7 (23.3%) 78 (27.7%)  
Mean age at relapse 
(years) 
6.0 6.8 6.3 5.8  p 0.55 
Lineage #           p 0.0028 * 
pB 82 (84.5%) 59 (74.7%) 55 (73.3%) 15 (50.0%) 211 (75.1%)  
T 7 (7.2%) 10 (12.6%) 15 (20.0%) 9 (30.0%) 41 (14.6%)  
Other 2 (2.1%) 1 (1.3%) 0 0 3 (1.1%)  
Not known 6 (6.2%) 9 (11.4%) 5 (6.7%) 6 (20.0%) 26 (9.2%)  
Site of relapse #           p 0.2304 
CNS 57 (58.8%) 51 (64.5%) 44 (58.7%) 15 (50.0%) 167 (59.4%)  
Testis 34 (35.0%) 17 (21.5%) 14 (18.7%) 8 (26.7%) 73 (26.0%)  
Mediastinum 1 (1.0%) 2 (2.6%) 8 (10.7%) 3 (10.0%) 15 (5.0%)  
CNS+other 2 (2.1%) 3 (3.8%) 5 (6.6%) 1 (3.3%) 11 (3.9%)  
CNS+ cerebral parenchima 1 0 2 1 4  
CNS+testis 0 2 1 0 3  
CNS+mediastinum 0 0 2 0 2  
CNS+eye 0 1 0 0 1  
Eye 0 3 0 1 3  
Lymph-nodes 1 1 0 1 3  
Other sites (liver, ovary, kidney, skin..) 2 2 4 1 9  
Other 3 (3.1%) 6 (7.6%) 4 (5.3%) 3 (10.0%) 16 (5.7%)  
Time to relapse #           p 0.0043* 
Very early 16 (16.5%) 27 (34.2%) 33 (44.0%) 11 (36.7%) 87 (31.0%)  
Early 33 (34.0%) 28 (35.4%) 26 (34.7%) 10 (33.3%) 97 (34.5%)  
Late 42 (43.3%) 21 (26.6%) 16 (21.3%) 8 (26.7%) 87 (31.0%)  
not known 6 (6.2%) 3 (3.8%) 0 1 (3.3%) 10 (3.5%)  
Remission status at 
HSCT 
          p 0.0031* 
CR2 78 (80.4%) 58 (73.4%) 56 (74.7%) 12 (40.0%) 204 (72.6%)  
CR>2 13 (13.4%) 16 (20.3%) 15 (20.0%) 15 (50.0%) 59 (21.0%)  
no remission 6 (6.2%) 5 (6.3%) 4 (5.3%) 3 (10.0%) 18 (6.4%)  
TBI-based conditioning 
# 
          p 0.056 
Yes 82 (84.5%) 71 (89.9%) 55 (73.3%) 27 (90.0%) 235 (83.6%)  
No 14  (14.5%) 7 (8.9%) 18 (24.0%) 3 (10.0%) 42 (15.0%)  
not known 1 (1.0%) 1 (1.2%) 2 (2.7%) 0 4 (1.4%)  
Source of PBSC #           p<0.0001* 
BM 60 (61.9%) 71 (89.9%) 52 (69.4%) 7 (23.3%) 190 (67.6%)  
CB 0 2 (2.5%) 17 (22.6%) 1 (3.3%) 20 (7.1%)  
PBSC 36 (37.1%) 3 (3.8%) 6 (8.0%) 22 (73.4%) 67 (23.9%)  
BM+other 1 (1.0%) 3 (3.8%) 0 0 1 (0.4%)  
Year of HSCT           p<0.0001* 
1990-2000 57 (58.8%) 37 (46.8%) 7 (9.3%) 6 (20%) 107 (38.1%)  
2000-2015 40 (41.2%) 42 (53.2%) 68 (90.7%) 24 (80%) 174 (61.9%)  
 
Table I: Characteristics of 281 children who underwent HSCT for an isolated 
extramedullary relapse of ALL from 1990 to 2015 in Italy. * statistically significant (p<0.05). 
# analysis of significance performed on the most representative groups: Lineage (T , B), 
Site of relapse (CNS, Testits), Time to relapse (Very early, Early, late), TBI-based 
conditioning (Yes, No), source of cell (BM, CB, PBSC) 
Abbreviations; CNS central nervous system, HSCT hematopoietic stem cell transplantation, CR complete remission, TBI 
total body irradiation, PBSC peripheral blood stem cell, BM bone marrow, PB peripheral blood 
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Conditioning Regimen number of patients 
Cyclo+Thiotepa+ TBI 50 (17.8%) 
Ara-c +TBI 45 (16%) 
Thiotepa+ 
Cyclo+ATG+TBI 24 (8.5%) 
Ethoposide+TBI 18 (6.4%) 
Vincristine+Cyclo+TBI 18 (6.4%) 
Ethoposide+Cyclo+TBI 14 (5%) 
Thiotepa+ Fludara+TBI 11 (3.9%) 
Cyclo+TBI 10 (3.5%) 
Thiotepa+L-Pham+TBI 10 (3.5%) 
others + TBI 62 (22%) 
NON TBI 19 (6.8%) 
Bus+Thiotepa+Cyclo 10 
Bus+Cyclo 5 
Bus+Thiotepa+Fludara 4 
 
Table II: Conditioning Regimens.  
Abbreviatios: Cyclo  Cyclophosphamide, TBI total body irradiation, Ara-C Cytarabine, ATG anti-thymocyte 
globulin, Fludara Fludarabine, L-pham Melphalan, Bus Busulphan 
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Figure I: Overall survival of patients transplanted for extramedullary relapse of ALL: stratification 
per HSCT donor  
 
 
 
Figure II: Overall survival of patients transplanted for extramedullary relapse of ALL: stratification 
per remission status at HSCT 
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A  
 
B  
 
C  
Figure III: Overall survival for patients with very early (A),  early (B) and late (C) relapse: auto 
HSCT versus allo HSCT  
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Characteristics Categories # 
Pts 
Events 10-y 
OS % 
(SE%) 
Univariable 
P-value 
Multivariable 
P-value 
Hazard 
Ratio 
(95% CI) 
Age < 10 yrs 
> 10 yrs 
215 
48 
82 
16 
59 (4) 
66 (7) 
0.50 -  
Gender Female 
Male 
73 
190 
25 
73 
60 (6) 
60 (4) 
0.58 -  
Lineage  B 
T 
203 
33 
76 
9 
61 (4) 
68 (9) 
0.42 -  
Relapse site testis 
CNS 
72 
154 
24 
60 
67 (6) 
58 (4) 
0.23 0.56  
TBI 
conditioning 
regimen 
No 
Yes 
36 
224 
17 
80 
43 
(10) 
60 (4) 
0.21 0.86  
Years of HSCT Before 2000 
After 2000 
94 
169 
49 
49 
51 (5) 
65 (4) 
0.0064 0.0035 0.5 (0.3-0.8) 
HSCT type Autologous 
Allogeneic 
91 
172 
36 
62 
62 (5) 
60 (4) 
0.63 -  
Status at HSCT Second CR 
Other CR 
204 
59 
65 
33 
65 (4) 
44 (7) 
<0.0001 0.0005 2.3 (1.4-
30.7) 
 
Table III: Multivariable analysis of factors influencing outcome in patients with IEMR. 
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Discussion 
Although the vast majority of children affected by ALL are cured with current 
protocols, relapses still occur and pose remarkable challenges to pediatric 
hematologists. Allo HSCT is currently used to treat patients in CR2 with high-risk 
features (early and isolated marrow relapse, recurrence of T lineage ALL [1,11]), 
and is now considered in those patients who present MRD positivity above certain 
thresholds at the end of induction therapy [12,13]. Treatment of extramedullary 
relapse is less well established. The absence of BM involvement is traditionally 
considered a favorable prognostic feature [14], and these patients are commonly 
treated with intensive systemic and intrathecal chemotherapy (CT) followed by 
either cranio-spinal or cranial irradiation (RT) [5, 7, 15, 16]. EFS with this approach 
ranges from 45% [3, 7, 17, 18] to 70% [15]. Despite the high curative rates obtained 
in the two Children Oncology Group trials [15,19], with global EFS at 5 years 
approaching 70%, for particular subgroups of IEMR, prognosis is still dismal. Very 
early and early IEMR or ICNS relapses show survival probability of only 20-30% in 
most studies; in this regard, Tallen [3] reported 33% EFS for very early ICNS 
relapse. Similarly, in other published papers, RFS and EFS ranged from 20% to 
35% for very early/early IEMR [7,17,18]. 
HSCT has been used for treatment of IEMR, but published data are conflicting and 
limited to small numbers of patients [6, 20-22]. Our previous work [9] analyzed the 
outcome of 69 patients with early (<30 months from diagnosis) ICNS relapse 
treated with either auto HSCT or CT/RT: EFS with auto HSCT was clearly superior 
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to CT/RT (56% vs 12%). Moreover, in another report, we demonstrated that auto 
HSCT performed in CR2 offers a better chance of cure than when it is employed 
in subsequent CR [10]. More recent papers compared allogeneic HSCT with CT/RT 
in patients with ICNS relapse of ALL. Eapen and colleagues [5] reported a 
comparable outcome in 209 patients treated with CT/RT or MFD HSCT: EFS were 
66% and 58% respectively. Similarly, other studies [2, 7] did not find any statistical 
difference when patients with IEMR in CR2 were treated with either HSCT or 
chemotherapy, but numbers of patients treated with HSCT were very small. 
In this study, we present the largest cohort of patients with IEMR of ALL, 
morphologically defined, and the largest number of HSCT ever performed for this 
indication, with a long follow up (up to 26 years from HSCT). 
OS and DFS at 10 years were the same for autologous, MFD and MUD HSCT, 
being around 60% and 70%. Even if a control group of patients treated with CT/RT 
was not included in the study, our results are comparable with those reported in 
previous studies, since published OS with CT/RT is 45-70% [3, 5, 7, 15-17, 19]. 
Moreover, if only patients in second CR are considered, as in all published series, 
the OS of 64% at 10 years is in line with the most favorable reports [15,19].  
Notably, in our study, the use of HSCT seemed to abrogate the impact of some 
“classical” prognostic factors like site of IEMR, duration of first remission and ALL 
blast immune-phenotype. If the site of relapse was considered, OS was only 
slightly better for testicular relapse. Neither duration of CR1 nor ALL immune-
phenotype affected the outcome in univariable and multivariable analysis; in fact, 
the only factors influencing outcome resulted to be year of HSCT and remission 
status at transplantation. Regarding the prognostic impact of year of 
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transplantation, this likely reflects the improvement in supportive therapy and donor 
selection. About the prognostic significance of remission status before HSCT, 
these data confirm what we reported previously [10], namely that survival for 
children transplanted in CR2, morphologically defined, is significantly better than 
for patients transplanted in subsequent remission. This observation emphasizes 
the importance of identifying those patients at higher risk of further relapse, who, 
thus, may benefit of HSCT soon after achievement of CR2. Very early and early 
IEMR or ICNS relapses treated with CT/RT have been previously shown to have a 
survival probability around 20-30% [3, 7, 17, 18], while the use of HSCT in this 
study resulted into an OS probability of 53% for early relapses and 52% for very 
early relapses. This result is even more striking considering that patients with third 
or subsequent CR and even with active disease were included in this analysis. 
Therefore, given the high risk of further relapse of very early/early iIEMR treated 
with CT/RT and the poor outcome with HSCT performed after a second relapse, 
our data support the choice of HSCT in patients experiencing very early/early IEMR 
once that a second CR is achieved. 
The 44% OS and  39% DFS at 10 years obtained in patients transplanted in third 
or subsequent CR (59 cases) are remarkable, these results comparing favorably 
with those previously published by other goups with shorter follow up. In fact, in 
this subgroup of patients, EFS of 35% at 3 years after MUD HSCT was reported 
(21) whileother studies [23-25] reported EFS ranging from 20 to 48% for children 
with ALL transplanted from MFD or MUD in CR3. 
Furthermore, no difference in outcome was observed regarding the type of HSCT. 
This is in line with our previous observation in a smaller group of patients in which 
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auto HSCT had the same chance to cure children with ICNS relapsed ALL than 
allogeneic (MFD) HSCT [9]. The present data strengthen this observation, 
widening the comparison with inclusion of MUD HSCT and (even if with a low 
number of cases) with haplo HSCT. It is possible that in extra medullary sites, the 
GvL effect be less relevant [26] and that the good results obtained with HSCT may 
be due to the inclusion of TBI in the conditioning regimen. In fact, TBI-containing 
regimens showed better survival rates compared with non-TBI regimens. 
Surprisingly, TRM at 10 years was no different between auto, MFD and MUD 
HSCT (11%, 16% and 16% respectively).  
This study shows that both auto and allo HSCT are effective treatment for IEMR of 
ALL. Auto HSCT can cure children with late IEMR with efficacy at least comparable 
to that of CT/RT. Despite the possibility of long-term complications, auto HSCT, 
compared to a second complete course of chemo-radiotherapy, may allow a 
shorter duration of treatment, this resulting into a better quality of life for patients 
and their families. Furthermore, our results indicate that particularly children with 
very early and early IEMR may benefit from HSCT, either autologous or allogeneic. 
Notably, autologous stem cell use may significantly reduce the time patients wait 
before transplantation, the risk of GVHD, of infection and graft failure associated 
with allogeneic HSCT. Although the retrospective nature of this study is an 
important limitation, the large number of patients with iEMR and the very long follow 
up strengthen our results Data from contemporary treatment protocols, which 
include MRD assessment for stratifying patients experiencing disease recurrence, 
will further clarify the role of HSCT in the treatment of extramedullary relapse of 
pediatric ALL. 
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